WO2022095904A1 - 吡唑并哒嗪酮化合物、其药物组合物及其用途 - Google Patents
吡唑并哒嗪酮化合物、其药物组合物及其用途 Download PDFInfo
- Publication number
- WO2022095904A1 WO2022095904A1 PCT/CN2021/128460 CN2021128460W WO2022095904A1 WO 2022095904 A1 WO2022095904 A1 WO 2022095904A1 CN 2021128460 W CN2021128460 W CN 2021128460W WO 2022095904 A1 WO2022095904 A1 WO 2022095904A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membered
- group
- independently selected
- alkyl
- optionally substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
- -1 Pyrazolopyridazinone compound Chemical class 0.000 title claims description 108
- 150000001875 compounds Chemical class 0.000 claims abstract description 319
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims abstract description 38
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims description 230
- 125000000217 alkyl group Chemical group 0.000 claims description 200
- 125000006848 alicyclic heterocyclic group Chemical group 0.000 claims description 187
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 125
- 229910052739 hydrogen Inorganic materials 0.000 claims description 112
- 239000001257 hydrogen Substances 0.000 claims description 107
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 95
- 229910052757 nitrogen Inorganic materials 0.000 claims description 95
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 90
- 125000002723 alicyclic group Chemical group 0.000 claims description 87
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 87
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 85
- 125000004429 atom Chemical group 0.000 claims description 72
- 125000001072 heteroaryl group Chemical group 0.000 claims description 62
- 125000004043 oxo group Chemical group O=* 0.000 claims description 61
- 125000003342 alkenyl group Chemical group 0.000 claims description 60
- 125000005843 halogen group Chemical group 0.000 claims description 60
- 238000002360 preparation method Methods 0.000 claims description 59
- 125000005842 heteroatom Chemical group 0.000 claims description 56
- 125000002950 monocyclic group Chemical group 0.000 claims description 56
- 125000006413 ring segment Chemical group 0.000 claims description 54
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 53
- 125000000304 alkynyl group Chemical group 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000003118 aryl group Chemical group 0.000 claims description 48
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 44
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims description 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 43
- 239000012453 solvate Substances 0.000 claims description 42
- 239000002207 metabolite Substances 0.000 claims description 40
- 229910052731 fluorine Inorganic materials 0.000 claims description 38
- 230000000155 isotopic effect Effects 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 33
- 239000000651 prodrug Substances 0.000 claims description 33
- 229940002612 prodrug Drugs 0.000 claims description 33
- 239000011737 fluorine Substances 0.000 claims description 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 239000001301 oxygen Chemical group 0.000 claims description 28
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 27
- 229910052717 sulfur Inorganic materials 0.000 claims description 25
- 125000004437 phosphorous atom Chemical group 0.000 claims description 24
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 23
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 22
- 229910052698 phosphorus Inorganic materials 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 239000000460 chlorine Substances 0.000 claims description 19
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 16
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 15
- 125000001931 aliphatic group Chemical group 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 11
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical group 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000003003 spiro group Chemical group 0.000 claims description 6
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 150000001336 alkenes Chemical class 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010027201 Meningitis aseptic Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 3
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000001174 sulfone group Chemical group 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 241000124740 Bocaparvovirus Species 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000709687 Coxsackievirus Species 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 241000709661 Enterovirus Species 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 2
- 241000701806 Human papillomavirus Species 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 241001263478 Norovirus Species 0.000 claims description 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 241000315672 SARS coronavirus Species 0.000 claims description 2
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010043276 Teratoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 201000009365 Thymic carcinoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- 206010004398 benign neoplasm of skin Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 2
- 201000000289 malignant teratoma Diseases 0.000 claims description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 6
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 claims 2
- 150000002430 hydrocarbons Chemical group 0.000 claims 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 240000007839 Kleinhovia hospita Species 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000005475 oxolanyl group Chemical group 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 238000006243 chemical reaction Methods 0.000 description 73
- 239000000243 solution Substances 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 238000000034 method Methods 0.000 description 44
- 239000007787 solid Substances 0.000 description 37
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 36
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 36
- 239000000203 mixture Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000012065 filter cake Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 9
- 150000001721 carbon Chemical group 0.000 description 9
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 7
- JMIBIPMJFZTDNN-UHFFFAOYSA-N COC(C=C1)=CC(OC)=C1N1N=C(C(C(C=C2)=CC=C2Br)=O)C(O)=CC1=O Chemical compound COC(C=C1)=CC(OC)=C1N1N=C(C(C(C=C2)=CC=C2Br)=O)C(O)=CC1=O JMIBIPMJFZTDNN-UHFFFAOYSA-N 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101001090688 Homo sapiens Lymphocyte cytosolic protein 2 Proteins 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 125000003367 polycyclic group Chemical group 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 238000006619 Stille reaction Methods 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 238000006880 cross-coupling reaction Methods 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 4
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 4
- ZTSBAKBXEJGGSV-UHFFFAOYSA-N CC1=CC=CC(F)=C1NNC(C(CC(OC)=O)=O)C(OC)=O Chemical compound CC1=CC=CC(F)=C1NNC(C(CC(OC)=O)=O)C(OC)=O ZTSBAKBXEJGGSV-UHFFFAOYSA-N 0.000 description 4
- FIIKRMOCEOAVAN-UHFFFAOYSA-N COC(CC(CC(C(C=C1)=CC=C1Br)=O)=O)=O Chemical compound COC(CC(CC(C(C=C1)=CC=C1Br)=O)=O)=O FIIKRMOCEOAVAN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940125833 compound 23 Drugs 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- YEHZWOBPONLEEH-UHFFFAOYSA-N 4-bromo-n-methoxy-n-methylbenzamide Chemical compound CON(C)C(=O)C1=CC=C(Br)C=C1 YEHZWOBPONLEEH-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 3
- ZBSDRVIFOQCJEJ-UHFFFAOYSA-N CC1=CC=CC(F)=C1N(C(C=C1Cl)=O)N=C1C#N Chemical compound CC1=CC=CC(F)=C1N(C(C=C1Cl)=O)N=C1C#N ZBSDRVIFOQCJEJ-UHFFFAOYSA-N 0.000 description 3
- HENGSZSFISYLSY-UHFFFAOYSA-N CC1=CC=CC(F)=C1N1N=C(C(OC)=O)C(O)=CC1=O Chemical compound CC1=CC=CC(F)=C1N1N=C(C(OC)=O)C(O)=CC1=O HENGSZSFISYLSY-UHFFFAOYSA-N 0.000 description 3
- AEAHAWMGNSLOAH-UHFFFAOYSA-N CC1=CC=CC(F)=C1N1N=C2C(N)=NNC2=CC1=O Chemical compound CC1=CC=CC(F)=C1N1N=C2C(N)=NNC2=CC1=O AEAHAWMGNSLOAH-UHFFFAOYSA-N 0.000 description 3
- PNOMFBRFKHGESC-UHFFFAOYSA-N CC1=CC=CC(OC)=C1N1N=C(C(OC)=O)C(O)=CC1=O Chemical compound CC1=CC=CC(OC)=C1N1N=C(C(OC)=O)C(O)=CC1=O PNOMFBRFKHGESC-UHFFFAOYSA-N 0.000 description 3
- TZDACFFMPJJPNR-UHFFFAOYSA-N COC(C=C1)=CC(OC)=C1N1N=C2C(C(C=C3)=CC=C3Br)=NNC2=CC1=O Chemical compound COC(C=C1)=CC(OC)=C1N1N=C2C(C(C=C3)=CC=C3Br)=NNC2=CC1=O TZDACFFMPJJPNR-UHFFFAOYSA-N 0.000 description 3
- PIHNGDZUCVQBEY-UHFFFAOYSA-N COC1=CC=CC(F)=C1N1N=C(C(C(C=C2)=CC=C2Br)=O)C(O)=CC1=O Chemical compound COC1=CC=CC(F)=C1N1N=C(C(C(C=C2)=CC=C2Br)=O)C(O)=CC1=O PIHNGDZUCVQBEY-UHFFFAOYSA-N 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010575 fractional recrystallization Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- 239000012414 tert-butyl nitrite Substances 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- VHHKZASLPJMWJI-UHFFFAOYSA-N 2-fluoro-6-methoxyaniline Chemical compound COC1=CC=CC(F)=C1N VHHKZASLPJMWJI-UHFFFAOYSA-N 0.000 description 2
- CMVJYZNBMRJICR-UHFFFAOYSA-N 2-fluoro-6-methylaniline Chemical compound CC1=CC=CC(F)=C1N CMVJYZNBMRJICR-UHFFFAOYSA-N 0.000 description 2
- HKOJYPPTIPJZAZ-UHFFFAOYSA-N 2-methoxy-6-methylaniline Chemical compound COC1=CC=CC(C)=C1N HKOJYPPTIPJZAZ-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- MJKFVDFEGDQLNT-UHFFFAOYSA-N CC(C)(C)OC(NC(C(C1CC1)=CC=C1)=C1F)=O Chemical compound CC(C)(C)OC(NC(C(C1CC1)=CC=C1)=C1F)=O MJKFVDFEGDQLNT-UHFFFAOYSA-N 0.000 description 2
- DQBADGJLXCPWCG-UHFFFAOYSA-N CC1=CC=CC(F)=C1N1N=C(C(N)=O)C(O)=CC1=O Chemical compound CC1=CC=CC(F)=C1N1N=C(C(N)=O)C(O)=CC1=O DQBADGJLXCPWCG-UHFFFAOYSA-N 0.000 description 2
- KSCHBPYRKVKHOK-UHFFFAOYSA-N CC1=CC=CC(F)=C1N1N=C2C(Br)=NNC2=CC1=O Chemical compound CC1=CC=CC(F)=C1N1N=C2C(Br)=NNC2=CC1=O KSCHBPYRKVKHOK-UHFFFAOYSA-N 0.000 description 2
- YAIWUXRENMKACD-UHFFFAOYSA-N CC1=CC=CC(OC)=C1N(C(C=C1NN2)=O)N=C1C2=O Chemical compound CC1=CC=CC(OC)=C1N(C(C=C1NN2)=O)N=C1C2=O YAIWUXRENMKACD-UHFFFAOYSA-N 0.000 description 2
- UTNWWPKWIPQJEW-UHFFFAOYSA-N CC1=CC=CC(OC)=C1N1N=C(C(OC)=O)C(Cl)=CC1=O Chemical compound CC1=CC=CC(OC)=C1N1N=C(C(OC)=O)C(Cl)=CC1=O UTNWWPKWIPQJEW-UHFFFAOYSA-N 0.000 description 2
- UYXIWXWAFRVCAI-UHFFFAOYSA-N CC1=CC=CC(OC)=C1N1N=C2C(Cl)=NNC2=CC1=O Chemical compound CC1=CC=CC(OC)=C1N1N=C2C(Cl)=NNC2=CC1=O UYXIWXWAFRVCAI-UHFFFAOYSA-N 0.000 description 2
- FNUWQEMVWUZABI-UHFFFAOYSA-N COC(C(C(Cl)=CC1=O)=NN1C(C(OC)=CC=C1)=C1F)=O Chemical compound COC(C(C(Cl)=CC1=O)=NN1C(C(OC)=CC=C1)=C1F)=O FNUWQEMVWUZABI-UHFFFAOYSA-N 0.000 description 2
- IERBIKKIYVTUGY-UHFFFAOYSA-N COC(C(C(NN)=CC1=O)=NN1C(C(OC)=CC=C1)=C1F)=O Chemical compound COC(C(C(NN)=CC1=O)=NN1C(C(OC)=CC=C1)=C1F)=O IERBIKKIYVTUGY-UHFFFAOYSA-N 0.000 description 2
- JCJFIYUFCJTWNK-UHFFFAOYSA-N COC1=CC(OC)=C(CN(C(C2=NN3C(C=CC(OC)=C4)=C4OC)=CC3=O)N=C2C(C=C2)=CC=C2Br)C=C1 Chemical compound COC1=CC(OC)=C(CN(C(C2=NN3C(C=CC(OC)=C4)=C4OC)=CC3=O)N=C2C(C=C2)=CC=C2Br)C=C1 JCJFIYUFCJTWNK-UHFFFAOYSA-N 0.000 description 2
- SBRLDJHDDPKUQV-UHFFFAOYSA-N COC1=CC=CC(F)=C1N1N=C2C(C(C=C3)=CC=C3Br)=NNC2=CC1=O Chemical compound COC1=CC=CC(F)=C1N1N=C2C(C(C=C3)=CC=C3Br)=NNC2=CC1=O SBRLDJHDDPKUQV-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- AFFVLIBNBBNYEQ-UHFFFAOYSA-N O=C1N(C(C(C2CC2)=CC=C2)=C2F)N=C2C(C(C=C3)=CC=C3Br)=NNC2=C1 Chemical compound O=C1N(C(C(C2CC2)=CC=C2)=C2F)N=C2C(C(C=C3)=CC=C3Br)=NNC2=C1 AFFVLIBNBBNYEQ-UHFFFAOYSA-N 0.000 description 2
- WOSOXBIADMGBJT-UHFFFAOYSA-N OC(C(C(C(C=C1)=CC=C1Br)=O)=NN1C(C(C2CC2)=CC=C2)=C2F)=CC1=O Chemical compound OC(C(C(C(C=C1)=CC=C1Br)=O)=NN1C(C(C2CC2)=CC=C2)=C2F)=CC1=O WOSOXBIADMGBJT-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- LSKYURVDOIDSCG-UHFFFAOYSA-N [4-(4-methylpiperazin-1-yl)phenyl]boronic acid Chemical compound C1CN(C)CCN1C1=CC=C(B(O)O)C=C1 LSKYURVDOIDSCG-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- GTXOIZFULNJWAU-UHFFFAOYSA-N pyrazolo[4,3-c]pyridazin-3-one Chemical class C1=NN=C2C(=O)N=NC2=C1 GTXOIZFULNJWAU-UHFFFAOYSA-N 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 1
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- UNFHOXBRZTWFAU-UHFFFAOYSA-N 1,6-dihydropyridazine-3-carbonitrile Chemical compound N#CC1=NNCC=C1 UNFHOXBRZTWFAU-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical compound CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 description 1
- SQMVRFXDBRYXFQ-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine Chemical compound C1N(C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 SQMVRFXDBRYXFQ-UHFFFAOYSA-N 0.000 description 1
- DHODROHJSUZIEC-UHFFFAOYSA-N 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazin-2-one Chemical compound C1C(=O)N(C)CCN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 DHODROHJSUZIEC-UHFFFAOYSA-N 0.000 description 1
- RDFJBDMCBVSCFI-UHFFFAOYSA-N 1-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine Chemical compound C1CN(C)CCN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 RDFJBDMCBVSCFI-UHFFFAOYSA-N 0.000 description 1
- IQKOVLZJPVVLOZ-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl piperazine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CN(C(=O)OC(C)(C)C)CCN1 IQKOVLZJPVVLOZ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 101710112812 14-3-3 protein Proteins 0.000 description 1
- MGHNDJJPPOAIHK-UHFFFAOYSA-N 1H-inden-1-yl Chemical group C1=CC=C2[CH]C=CC2=C1 MGHNDJJPPOAIHK-UHFFFAOYSA-N 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- SDUBUJREBNMPPG-UHFFFAOYSA-N 2,5-dimethyl-1,3-dioxin-4-one Chemical compound CC=1C(OC(OC1)C)=O SDUBUJREBNMPPG-UHFFFAOYSA-N 0.000 description 1
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 1
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- QTMAZYGAVHCKKX-UHFFFAOYSA-N 2-[(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]propane-1,3-diol Chemical compound NC1=NC=NC2=C1C(Br)=CN2COC(CO)CO QTMAZYGAVHCKKX-UHFFFAOYSA-N 0.000 description 1
- PAYROHWFGZADBR-UHFFFAOYSA-N 2-[[4-amino-5-(5-iodo-4-methoxy-2-propan-2-ylphenoxy)pyrimidin-2-yl]amino]propane-1,3-diol Chemical compound C1=C(I)C(OC)=CC(C(C)C)=C1OC1=CN=C(NC(CO)CO)N=C1N PAYROHWFGZADBR-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- IFRXOKRMTNFTGB-UHFFFAOYSA-N 2-cyclopropyl-6-fluoroaniline Chemical compound Nc1c(F)cccc1C1CC1 IFRXOKRMTNFTGB-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- WFJXYIUAMJAURQ-UHFFFAOYSA-N 2-propan-2-ylsulfinylpropane Chemical compound CC(C)S(=O)C(C)C WFJXYIUAMJAURQ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- RNJOKCPFLQMDEC-UHFFFAOYSA-N 4(R),8-dimethyl-trans-2-nonenoyl-CoA Chemical compound COC(=O)CC(=O)CC(=O)OC RNJOKCPFLQMDEC-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- GSDQYSSLIKJJOG-UHFFFAOYSA-N 4-chloro-2-(3-chloroanilino)benzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1NC1=CC=CC(Cl)=C1 GSDQYSSLIKJJOG-UHFFFAOYSA-N 0.000 description 1
- GHDZRAXCPMTNLS-UHFFFAOYSA-N 4h-pyridazin-3-one Chemical compound O=C1CC=CN=N1 GHDZRAXCPMTNLS-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- VKLKXFOZNHEBSW-UHFFFAOYSA-N 5-[[3-[(4-morpholin-4-ylbenzoyl)amino]phenyl]methoxy]pyridine-3-carboxamide Chemical compound O1CCN(CC1)C1=CC=C(C(=O)NC=2C=C(COC=3C=NC=C(C(=O)N)C=3)C=CC=2)C=C1 VKLKXFOZNHEBSW-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- IJRKLHTZAIFUTB-UHFFFAOYSA-N 5-nitro-2-(2-phenylethylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCC1=CC=CC=C1 IJRKLHTZAIFUTB-UHFFFAOYSA-N 0.000 description 1
- UNFIFDGZNSVRRI-UHFFFAOYSA-N 6-[2-(4-bromophenyl)-2-oxoethyl]-2,2-dimethyl-1,3-dioxin-4-one Chemical compound CC1(OC(=CC(O1)=O)CC(C1=CC=C(C=C1)Br)=O)C UNFIFDGZNSVRRI-UHFFFAOYSA-N 0.000 description 1
- GDUANFXPOZTYKS-UHFFFAOYSA-N 6-bromo-8-[(2,6-difluoro-4-methoxybenzoyl)amino]-4-oxochromene-2-carboxylic acid Chemical compound FC1=CC(OC)=CC(F)=C1C(=O)NC1=CC(Br)=CC2=C1OC(C(O)=O)=CC2=O GDUANFXPOZTYKS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XASOHFCUIQARJT-UHFFFAOYSA-N 8-methoxy-6-[7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]-2-(2,2,2-trifluoroethyl)-3,4-dihydroisoquinolin-1-one Chemical compound C(N1C(=O)C2=C(OC)C=C(C=3N4C(=NC=3)C=C(C=C4)OCCN3CCOCC3)C=C2CC1)C(F)(F)F XASOHFCUIQARJT-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- IYHHRZBKXXKDDY-UHFFFAOYSA-N BI-605906 Chemical compound N=1C=2SC(C(N)=O)=C(N)C=2C(C(F)(F)CC)=CC=1N1CCC(S(C)(=O)=O)CC1 IYHHRZBKXXKDDY-UHFFFAOYSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- BGGALFIXXQOTPY-NRFANRHFSA-N C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC Chemical compound C1(=C(C2=C(C=C1)N(C(C#N)=C2)C[C@@H](N1CCN(CC1)S(=O)(=O)C)C)C)CN1CCC(CC1)NC1=NC(=NC2=C1C=C(S2)CC(F)(F)F)NC BGGALFIXXQOTPY-NRFANRHFSA-N 0.000 description 1
- CPQFNUPJLBSUFV-UHFFFAOYSA-N CC(C)(OC(C(C(C(C=C1)=CC=C1Br)=O)NNC(C(OC)=CC=C1)=C1F)=C1)OC1=O Chemical compound CC(C)(OC(C(C(C(C=C1)=CC=C1Br)=O)NNC(C(OC)=CC=C1)=C1F)=C1)OC1=O CPQFNUPJLBSUFV-UHFFFAOYSA-N 0.000 description 1
- AVNPAJUOEASNCG-UHFFFAOYSA-N CC1=CC=CC(OC)=C1N1N=C(C(NN)=O)C(NN)=CC1=O Chemical compound CC1=CC=CC(OC)=C1N1N=C(C(NN)=O)C(NN)=CC1=O AVNPAJUOEASNCG-UHFFFAOYSA-N 0.000 description 1
- KCLAZBQFYVMIBO-UHFFFAOYSA-N CC1=CC=CC(OC)=C1N1N=C(C(OC)=O)C(NN)=CC1=O Chemical compound CC1=CC=CC(OC)=C1N1N=C(C(OC)=O)C(NN)=CC1=O KCLAZBQFYVMIBO-UHFFFAOYSA-N 0.000 description 1
- XHTWFUFWKHIJEQ-UHFFFAOYSA-N CC1=CC=CC(OC)=C1NNC(C(CC(OC)=O)=O)C(OC)=O Chemical compound CC1=CC=CC(OC)=C1NNC(C(CC(OC)=O)=O)C(OC)=O XHTWFUFWKHIJEQ-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O Chemical compound CCN(CC1=NC2=C(N1)C1=CC=C(C=C1N=C2N)C1=NNC=C1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- WAQLKXFVLVWOTK-UHFFFAOYSA-N CN(CC1)CC=C1C(C=C1)=CC=C1C(C1=NN2C(C(OC)=CC=C3)=C3F)=NNC1=CC2=O Chemical compound CN(CC1)CC=C1C(C=C1)=CC=C1C(C1=NN2C(C(OC)=CC=C3)=C3F)=NNC1=CC2=O WAQLKXFVLVWOTK-UHFFFAOYSA-N 0.000 description 1
- QDPXDYOJMKUQJO-UHFFFAOYSA-N CN(CC1)CC=C1C(C=C1)=CC=C1C(C1=NN2C(C=CC(OC)=C3)=C3OC)=NNC1=CC2=O Chemical compound CN(CC1)CC=C1C(C=C1)=CC=C1C(C1=NN2C(C=CC(OC)=C3)=C3OC)=NNC1=CC2=O QDPXDYOJMKUQJO-UHFFFAOYSA-N 0.000 description 1
- FNTUQFQMKREVJJ-UHFFFAOYSA-N CN(CC1)CCC1C(C=C1)=CC=C1C(C1=NN2C(C(OC)=CC=C3)=C3F)=NNC1=CC2=O Chemical compound CN(CC1)CCC1C(C=C1)=CC=C1C(C1=NN2C(C(OC)=CC=C3)=C3F)=NNC1=CC2=O FNTUQFQMKREVJJ-UHFFFAOYSA-N 0.000 description 1
- MFIPORQTNLYLNH-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC=C1C(C1=NN2C(C(C3CC3)=CC=C3)=C3F)=NNC1=CC2=O Chemical compound CN(CC1)CCN1C(C=C1)=CC=C1C(C1=NN2C(C(C3CC3)=CC=C3)=C3F)=NNC1=CC2=O MFIPORQTNLYLNH-UHFFFAOYSA-N 0.000 description 1
- GEEMAKIELJCEIH-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC=C1C(C1=NN2C(C=CC(OC)=C3)=C3OC)=NN(CC(C=CC(OC)=C3)=C3OC)C1=CC2=O Chemical compound CN(CC1)CCN1C(C=C1)=CC=C1C(C1=NN2C(C=CC(OC)=C3)=C3OC)=NN(CC(C=CC(OC)=C3)=C3OC)C1=CC2=O GEEMAKIELJCEIH-UHFFFAOYSA-N 0.000 description 1
- YTKXMRVKWLTPIC-UHFFFAOYSA-N CN(CC1)CCN1C(C=C1)=CC=C1C(C1=NN2C(C=CC(OC)=C3)=C3OC)=NNC1=CC2=O Chemical compound CN(CC1)CCN1C(C=C1)=CC=C1C(C1=NN2C(C=CC(OC)=C3)=C3OC)=NNC1=CC2=O YTKXMRVKWLTPIC-UHFFFAOYSA-N 0.000 description 1
- SQEAQTHZKICWNT-UHFFFAOYSA-N CN(CCN(C1)C(C=C2)=CC=C2C(C2=NN3C(C(OC)=CC=C4)=C4F)=NNC2=CC3=O)C1=O Chemical compound CN(CCN(C1)C(C=C2)=CC=C2C(C2=NN3C(C(OC)=CC=C4)=C4F)=NNC2=CC3=O)C1=O SQEAQTHZKICWNT-UHFFFAOYSA-N 0.000 description 1
- VWPWXLGVDDVUQW-UHFFFAOYSA-N COC(C(C(O)=CC1=O)=NN1C(C(OC)=CC=C1)=C1F)=O Chemical compound COC(C(C(O)=CC1=O)=NN1C(C(OC)=CC=C1)=C1F)=O VWPWXLGVDDVUQW-UHFFFAOYSA-N 0.000 description 1
- LXBUGCSONHHWCD-UHFFFAOYSA-N COC(CC(C(C(C(C=C1)=CC=C1Br)=O)=CNNC(C=CC(OC)=C1)=C1OC)=O)=O Chemical compound COC(CC(C(C(C(C=C1)=CC=C1Br)=O)=CNNC(C=CC(OC)=C1)=C1OC)=O)=O LXBUGCSONHHWCD-UHFFFAOYSA-N 0.000 description 1
- USRMPBUEMLPDHM-UHFFFAOYSA-N COC(CC(C(C(C(C=C1)=CC=C1Br)=O)NNC(C(C1CC1)=CC=C1)=C1F)=O)=O Chemical compound COC(CC(C(C(C(C=C1)=CC=C1Br)=O)NNC(C(C1CC1)=CC=C1)=C1F)=O)=O USRMPBUEMLPDHM-UHFFFAOYSA-N 0.000 description 1
- IYLMDEWRXIXZGL-UHFFFAOYSA-N COC(CC(C(C(C(C=C1)=CC=C1Br)=O)NNC(C=CC(OC)=C1)=C1OC)=O)=O Chemical compound COC(CC(C(C(C(C=C1)=CC=C1Br)=O)NNC(C=CC(OC)=C1)=C1OC)=O)=O IYLMDEWRXIXZGL-UHFFFAOYSA-N 0.000 description 1
- ALLPXBXUAQAXJJ-UHFFFAOYSA-N COC1=CC=CC(F)=C1N(C(C=C1NN2)=O)N=C1C2=O Chemical compound COC1=CC=CC(F)=C1N(C(C=C1NN2)=O)N=C1C2=O ALLPXBXUAQAXJJ-UHFFFAOYSA-N 0.000 description 1
- CVNSXPCTWPUTCC-UHFFFAOYSA-N COC1=CC=CC(F)=C1N1N=C2C(Cl)=NNC2=CC1=O Chemical compound COC1=CC=CC(F)=C1N1N=C2C(Cl)=NNC2=CC1=O CVNSXPCTWPUTCC-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- IZTRNCRMJZMJIQ-UHFFFAOYSA-N C[Si](C)(C)CCOCN(C1=C2)N=CC1=NNC2=O Chemical compound C[Si](C)(C)CCOCN(C1=C2)N=CC1=NNC2=O IZTRNCRMJZMJIQ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical group C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 208000010368 Extramammary Paget Disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000723543 Homo sapiens 14-3-3 protein theta Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 125000002575 PGE2 group Chemical group 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical compound C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000018420 bone fibrosarcoma Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000017563 cutaneous Paget disease Diseases 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- CCAFPWNGIUBUSD-UHFFFAOYSA-N diethyl sulfoxide Chemical compound CCS(=O)CC CCAFPWNGIUBUSD-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006262 isopropyl amino sulfonyl group Chemical group 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- IHCHOVVAJBADAH-UHFFFAOYSA-N n-[2-hydroxy-4-(1h-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2h-chromene-3-carboxamide Chemical compound C1C2=CC(OC)=CC=C2OCC1C(=O)NC(C(=C1)O)=CC=C1C=1C=NNC=1 IHCHOVVAJBADAH-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- LPOIGVZLNWEGJG-UHFFFAOYSA-N n-benzyl-5-(4-methylpiperazin-1-yl)-2-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C([N+]([O-])=O)C(NCC=2C=CC=CC=2)=C1 LPOIGVZLNWEGJG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- OKKJLVBELUTLKV-FIBGUPNXSA-N trideuteriomethanol Chemical compound [2H]C([2H])([2H])O OKKJLVBELUTLKV-FIBGUPNXSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present application relates to pyrazolopyridazinone compounds, specifically a pyrazolopyridazinone derivative with HPK1 inhibitory activity.
- Hematopoietic progenitor kinase 1 is a serine/threonine kinase originally cloned from hematopoietic progenitor cells (Hu, M.C. et al., Genes Dev. 1996; 10:2251-2264; Keifer, F. et al, The EMBO Journal 1996; 15:7013-7025), belonging to the mitogen-activated protein kinase kinase kinase kinase kinase kinase kinase-4, MAP4K family.
- HPK1 is concentrated in lymphoid organs or lymphoid tissues, such as bone marrow, lymph nodes, thymus, etc., and is mainly expressed in immune cells (T cells, B cells, dendritic cells, macrophages, etc.) (Hu, M.C. et al., Genes Dev. 1996;10:2251-2264). This has drawn attention to the immunomodulatory role of HPK1.
- HPK1 is a negative regulator of the T cell receptor (TCR) signaling pathway.
- TCR signaling causes activation of HPK1 and binding to SLP-76 protein (Lasserre, R. et al., J Cell Biol. 2011; 195: 839-853; Shui, J. et al., Nature Immuno. 2007; 8:84-91) .
- Activated HPK1 will phosphorylate the Ser376 residue of SLP-76, promoting the binding of SLP-76 to the 14-3-3 protein (Di Bartolo, V. et al., J. Exp. Med. 2007; 204: 681-691; Shui, J. et al., Nature Immuno. 2007;8:84-91).
- the SLP-76/14-3-3 interaction downregulates ERK signaling and calcium flux, and triggers ubiquitination of SLP-76 and degradation of the SLP-76 complex, blocking the TCR activation pathway, thereby inhibiting T cell function (Lasserre, 2007). R. et al, J. Cell Biol. 2011;195:839-853).
- HPK1 knockout mice have enhanced T cell function under antigen stimulation and produce more cytokines, such as IL-2 and IFN- ⁇ (Shui, J. et al., Nature Immuno. 2007; 8:84- 91; Alzabin, S. et al, J. Immunol. 2009; 182: 6187-6194; Alzabin, S. et al, Cancer Immunol. Immunol. 2010; 59: 419-429). Further studies showed that the negative regulation of immune cells by HPK1 was dependent on its kinase activity.
- mice with HPK1 kinase activity blocked had enhanced CD8 + T cell function, faster clearance of chronic lymphocytic meningitis virus, and better inhibition of tumor growth (Hernandez, S. et al., Cell Reports 2018;25:80-94).
- LLC Lewis lung cancer
- HPK1 levels were significantly downregulated in tissue from patients, suggesting that downregulation of HPK1 contributes to enhanced autoimmune responses.
- upregulation of HPK1 levels has been observed in various cancers, such as acute myeloid leukemia (Chen-Deutsch, X. et al., Leuk. Res.
- HPK1 is a potential target for the treatment of tumors and viral diseases.
- the development of small-molecule inhibitors of HPK1 kinase has important clinical prospects.
- some patent applications for HPK1 small molecule inhibitors have been published, such as WO2018049191, WO2018049200, WO2018102366, WO2018183964, WO2019090198, WO2019206049, WO2019238067 and WO2020092528, etc., there are still no drugs targeting HPK1 targets on the market. Therefore, the development of novel small-molecule HPK1 inhibitors with good activity is an urgent need.
- a main purpose of this application is to provide a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof ,
- R 1 is selected from:
- R a and R b are each independently selected from:
- R a and R b attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3-6 unitary unit that is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 11 Cycloaliphatic heterocyclyl;
- R 11 is selected from fluorine, chlorine, C 1-3 alkyl and hydroxyl
- Cy A is selected from a 6-10-membered aryl group or a 5-10-membered heteroaryl group that is unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 12 ;
- R 12 is selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 unsubstituted or optionally substituted with 1, 2 , 3, 4, 5 or 6 substituents independently selected from R 22 6 -alkynyl, 6-10-membered aryl, 5-10-membered heteroaryl, C 3-12 -membered cycloalkyl and 3-12-membered alicyclic heterocyclic group;
- R a2 , R b2 and R e2 are each independently selected from:
- R a2 and R b2 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3 that is unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 22 ⁇ 12-membered alicyclic heterocyclic group;
- R c2 and R f2 are each independently selected from: C 1-4 alkyl , C 2- 4 alkenyl, C 2-4 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-12 cycloalkyl and 3-12 membered alicyclic heterocyclic group;
- R c2 and R f2 attached to the same phosphorus atom together with the phosphorus atom to which they are attached form unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 22 ⁇ 12-membered alicyclic heterocyclic group;
- R d2 is selected from:
- R 22 is selected from:
- R a4 , R b4 and R e4 are each independently selected from:
- R a4 and R b4 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3 that is unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 32 ⁇ 10-membered alicyclic heterocyclic group;
- R c4 and R f4 are each independently selected from: C 1-4 alkyl , C 2- 4 alkenyl, C 2-4 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-10 cycloalkyl and 3-10 membered alicyclic heterocyclic group;
- R c4 and R f4 attached to the same phosphorus atom together with the phosphorus atom to which they are attached form unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R32 ⁇ 10-membered alicyclic heterocyclic group;
- R d4 is selected from:
- R 32 is selected from:
- R a6 , R b6 and R e6 are each independently selected from:
- R a6 and R b6 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form 3-8 unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R G membered alicyclic group;
- R c6 and R f6 are each independently selected from: C 1-4 alkyl, C 2-4 alkene, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R G base, C 2-4 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-8 cycloalkyl and 3-8 membered aliphatic heterocyclic group;
- R c6 and R f6 attached to the same phosphorus atom together with the phosphorus atom to which they are attached form 3-8 unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R G membered alicyclic group;
- R d6 is selected from:
- Cy B is selected from 6-10-membered aryl or 5-10-membered heteroaryl unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 13 ;
- R 13 is selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 unsubstituted or optionally substituted with 1, 2 , 3, 4, 5 or 6 substituents independently selected from R 23 6 -alkynyl, 6-10-membered aryl, 5-10-membered heteroaryl, C 3-12 -membered cycloalkyl and 3-12-membered alicyclic heterocyclic group;
- R a3 , R b3 and R e3 are each independently selected from:
- R a3 and R b3 attached to the same nitrogen atom together with their attached nitrogen atoms form a 3- to 12-membered alicyclic heterocyclic group
- R c3 and R f3 are each independently selected from: unsubstituted or optionally substituted with 1 , 2 , 3, 4 or 5 substituents independently selected from R 23 4 alkenyl, C 2-4 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-12 cycloalkyl and 3-12 membered alicyclic heterocyclic group;
- R c3 and R f3 attached to the same phosphorus atom together with the phosphorus atom to which they are attached form unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 23 ⁇ 12-membered alicyclic heterocyclic group;
- R d3 is selected from:
- R 23 is selected from:
- R a5 , R b5 and R e5 are each independently selected from:
- R a5 and R b5 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3 that is unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 33 ⁇ 10-membered alicyclic heterocyclic group;
- R c5 and R f5 are each independently selected from: unsubstituted or optionally substituted with 1 , 2 , 3, 4 or 5 substituents independently selected from R 33 4 alkenyl, C 2-4 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-10 cycloalkyl and 3-10 membered alicyclic heterocyclic group;
- R c5 and R f5 attached to the same phosphorus atom together with the phosphorus atom to which they are attached form 3 which is unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from R 33 ⁇ 10-membered alicyclic heterocyclic group;
- R d5 is selected from:
- R 33 is selected from:
- R a7 , R b7 and R e7 are each independently selected from:
- R a7 and R b7 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form 3-8 unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R G membered alicyclic group;
- R c7 and R f7 are each independently selected from: C 1-4 alkyl, C 2-4 alkene, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R G base, C 2-4 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-8 cycloalkyl and 3-8 membered aliphatic heterocyclic group;
- R d7 is selected from:
- R G is selected from:
- R 1 is selected from hydrogen, fluorine, cyano, methyl and methoxy.
- R x is selected from -OH, C 1-6 alkyl (such as methyl), C1-6 alkoxy (such as methoxy), -NH 2 , C 1-6 alkylamino (such as amino, di- methylamino),
- R 12 are independently selected from: fluorine, C 1-6 alkyl (such as methyl), C 1-6 alkoxy (such as methoxy), C 1-6 alkylaminomethyl (such as dimethylaminomethyl, methylaminomethyl);
- Cy B is selected from one of the following structures:
- R a3 and R b3 are independently selected from hydrogen, optionally substituted C 1-6 alkyl and C 3-6 cycloalkyl, or R a3 and R b3 together with the attached N atom form a 4-6 membered saturated lipid Heterocyclic group, the above-mentioned alicyclic heterocyclic group is optionally substituted; the substituent in the above-mentioned optional substituted situation is selected from hydroxyl, C 1-6 alkyl, and C 1-6 alkyl substituted by F;
- CyA is selected from the following structures:
- the Cy A is selected from the following structures:
- W 1 is selected from CH 2 or oxygen
- R T is selected from hydrogen or methyl
- RV is selected from fluorine or methyl, and the number of RV is 0, 1 or 2.
- the CyB is selected from the following structures:
- R 12 when CyA is a phenyl group, and R 12 is an alicyclic heterocyclic group, R 12 is attached at the para or meta position of the phenyl group.
- the compound of formula (I) comprises an isotopic label obtained by deuteration of1H.
- Some embodiments of the present application also provide a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, or isotopic label thereof , isomer or prodrug, and a pharmaceutically acceptable carrier.
- Some embodiments of the present application further provide a compound of formula (I) above or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or pro- A medicine, or the above-mentioned pharmaceutical composition, for preventing or treating a disease mediated by HPK1.
- Some embodiments of the present application further provide a compound of formula (I) above or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or pro-
- the medicine or the use of the above-mentioned pharmaceutical composition in the preparation of a medicine for preventing or treating diseases mediated by HPK1.
- Some embodiments of the present application further provide a compound of formula (I) above or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or pro-
- Some embodiments of the present application further provide a method of inhibiting HPK1 activity comprising administering to an individual a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph thereof , isotopic labels, isomers or prodrugs.
- Some embodiments of the present application further provide a method of treating a disease or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active Metabolites, polymorphs, isotopic labels, isomers or prodrugs.
- the disease is an HPK1 mediated disease.
- the compounds of formula (I) according to some embodiments of the present application have the effect of inhibiting the activity of HPK1.
- the diseases include one or more of benign or malignant tumors, myelodysplastic syndromes, and diseases caused by viruses.
- R 1 is selected from:
- R 1 is selected from hydrogen, fluorine, chlorine, bromine, cyano, C 1-4 alkyl, C 3-4 cycloalkyl, 3-4 membered alicyclic and -OR a .
- R 1 is selected from the group consisting of hydrogen, fluoro, cyano, methyl, ethyl, 1-propyl, isopropyl, cyclopropyl, methoxy, ethoxy, and cyclopropyloxy.
- R 1 is hydrogen
- R a and R b are each independently selected from hydrogen, C 1-3 alkyl, C 3-4 cycloalkyl, and 3-4 membered alicyclic;
- R a and R b attached to the same nitrogen atom together with the nitrogen atom to which they are attached form an unsubstituted 3- to 6-membered alicyclic heterocyclic group.
- R a and R b are each independently selected from hydrogen, methyl, ethyl, and cyclopropyl.
- Cy A is phenyl, naphthyl, or 5, 6, 7, 8 unsubstituted or optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12 , 9 or 10-membered heteroaryl, wherein the heteroaryl contains 1, 2 or 3 ring-forming heteroatoms, and the heteroatoms are selected from N, O, and S.
- the aryl or heteroaryl group of Cy A contains 1 R 12 substituent, which R 12 is a cyclic group selected from unsubstituted or optionally 1, 2 Or 3-membered aryl, 5-10-membered heteroaryl, C 3-7 cycloalkyl and 3-7-membered alicyclic heterocyclic groups substituted with substituents independently selected from R 22 , 3-7 membered Aliphatic heterocyclic group contains 1 or 2 ring-forming heteroatoms selected from N, O, S;
- the aryl or heteroaryl group of Cy A contains 2, 3 or 4 R 12 substituents, of which 1 R 12 is the above-mentioned cyclic group, and the remaining R 12 is independently selected from C 1-6 alkyl, halogen atom, cyano, -OR a2 and -NR a2 R b2 .
- the aryl or heteroaryl group of Cy A contains 1 R 12 substituent, which R 12 is a cyclic group selected from unsubstituted or optionally 1, 2 Or 3 substituents independently selected from R 22 substituted phenyl, 5-6 membered heteroaryl, C 3-6 cycloalkyl and 4, 5, 6, 7 membered aliphatic heterocyclyl, 4, 5, 6, 7-membered alicyclic heterocyclic group contains 1 or 2 ring-forming heteroatoms selected from N, O, S;
- the aryl or heteroaryl group of Cy A contains 2 or 3 R 12 substituents, of which 1 R 12 is the above-mentioned cyclic group, and the remaining R 12 is independently selected from C 1-6 alkyl, halogen atom, cyano group , -OR a2 and -NR a2 R b2 .
- Cy A is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12 .
- Cy A is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 12 , wherein, respectively, with aryl or Two R 12 substituents attached to adjacent two ring atoms on a heteroaryl group together with the two ring atoms to which they are attached form unsubstituted or optionally by 1, 2, 3 or 4 independent C 5 , C 6 , C 7 monocyclic alicyclic hydrocarbon group or 5-, 6-, 7-membered monocyclic alicyclic heterocyclic group substituted by the substituent of R 22 .
- Cy A is phenyl, 5- or 6-membered heteroaryl optionally substituted with 1, 2, or 3 substituents independently selected from R, wherein heteroaryl comprises 1 Or 2 heteroatoms selected from N, S, such as 1 N atom, 2 N atoms or 1 N atom and 1 S atom.
- Cy A is phenyl, pyridyl, pyrimidinyl, pyrazolyl, imidazolyl, thiazolyl, iso- Thiazolyl, oxazolyl or isoxazolyl.
- Cy A is phenyl, pyridyl, pyrazolyl, imidazolyl, or thiazolyl optionally substituted with 1, 2, or 3 substituents independently selected from R12 .
- the aryl or heteroaryl of Cy A contains 2, 3 or 4 R substituents, wherein two R are attached to two adjacent ring-forming atoms on the aryl or heteroaryl, respectively 12 Substituents together with the two ring-forming atoms form C 5-8 alicyclic hydrocarbon groups and 5-8 membered unsubstituted or optionally substituted by 1, 2 or 3 substituents independently selected from R 22 Aliphatic heterocyclic group; Alicyclic heterocyclic group contains 1, 2 or 3 ring-forming heteroatoms selected from N, O, S, and each R that is not ring-forming is independently selected from C 1-6 alkyl, halogen atom, cyano, -OR a2 and -NR a2 R b2 .
- the aryl or heteroaryl of Cy A contains 2, 3 or 4 R substituents, wherein two R are attached to two adjacent ring-forming atoms on the aryl or heteroaryl, respectively
- the 12 substituents together with the two ring-forming atoms form unsubstituted or optionally 1, 2 or 3 independently selected from oxo, RH , -( CH2 ) 0-2 -OH, - ( CH2 ) 0-2 - ORH , -( CH2 ) 0-2 - NH2 , -( CH2 ) 0-2 -NHR H and -( CH2 ) 0-2 -N( RH ) 2
- the 5-, 6-, and 7-membered monocyclic alicyclic heterocyclic group substituted by the group containing 1 or 2 ring-forming heteroatoms selected from N and O; From C 1-6 alkyl, halogen atom, cyano group, -OR a2 and -NR a2 R
- each R is independently selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 unsubstituted or optionally substituted with 1, 2 , 3, 4, 5 or 6 substituents independently selected from R 22 6 -alkynyl, 6-10-membered aryl, 5-10-membered heteroaryl, C 3-12 -membered cycloalkyl and 3-12-membered alicyclic heterocyclic group;
- each R is independently selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 unsubstituted or optionally substituted with 1, 2 , 3, 4, 5 or 6 substituents independently selected from R 22 6 -alkynyl, 6-10-membered aryl, 5-10-membered heteroaryl, C 3-10 -membered cycloalkyl and 3-10-membered alicyclic heterocyclic group;
- each R is independently selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 22 , 6-10-membered aryl, 5-10-membered heteroaryl, C 3-10 -membered cycloalkyl and 3-10-membered aliphatic heterocyclic group;
- each R is independently selected from:
- each R is independently selected from:
- each R is independently selected from:
- each R is independently selected from:
- R 12 is selected from 4-membered, 5-membered, 6-membered, 7-membered units that are unsubstituted or each optionally substituted with 1, 2, 3 substituents independently selected from R 22 Cycloaliphatic heterocyclic group and 7-membered, 8-membered, 9-membered, 10-membered bicyclic alicyclic heterocyclic group.
- R 12 is a substituted or unsubstituted monocyclic alicyclic heterocyclic group or bicyclic alicyclic heterocyclic group
- the bicyclic alicyclic heterocyclic group can be, for example, a bridged ring group or a spirocyclic group
- the bicyclic alicyclic heterocyclic group includes A1 ring and A2 ring, the A1 ring is directly connected to the aryl or heteroaryl group of Cy A , the A1 ring can be a 3-6 membered ring, and the total number of ring atoms of the bicyclic alicyclic heterocyclic group No more than 10.
- the alicyclic heterocyclic group of R 12 contains 1 or 2 ring-forming heteroatoms, and the ring-forming heteroatoms are selected from N, O, and S.
- each R 12 is independently selected from a C 1-6 alkyl group, a halogen atom, a cyano group, -OR a2 and -NR a2 R b2 .
- each R is independently selected from:
- R 22 is selected from oxo, hydroxyl, amino, cyano, C 1-3 alkylamino, C 1-3 alkoxy, 3-6 membered cycloalkyl and 3-6 membered monocyclic aliphatic Heterocyclyl;
- R 12 The two R 12 substituents connected to the adjacent two ring-forming atoms on the aryl or heteroaryl group of Cy A , respectively, and the two ring-forming atoms together form unsubstituted or each optionally by 1 , 2 or 3 substituents independently selected from R 22 substituted C 5 , C 6 , C 7 monocyclic alicyclic hydrocarbon group or 5-membered, 6-membered, 7-membered monocyclic alicyclic heterocyclic group;
- Cy A is selected from:
- each R 12 is independently selected from the group consisting of fluorine, chlorine, R G1 other than hydrogen, and -OR G1 ;
- Cy A contains 1 R 12 selected from one of the following structures, wherein the chemical bond terminal in the structural formula Indicates that it is connected to other atoms in the structure of formula (I) through this bond:
- Cy A contains 2 or 3 R 12 , wherein 1 R 12 is selected from one of the above structures, and the remaining R 12 is independently selected from: fluorine, chlorine, R G1 other than hydrogen, -OR G1 ;
- X is selected from CH and N;
- Y is selected from -CH2- , NH and O;
- E 1 and E 2 are independently selected from -CH 2 - and carbonyl, but E 1 and E 2 are not both carbonyl;
- R G2 is selected from hydrogen, -OR G1 and -N(R G1 ) 2 ;
- Each R G1 is independently selected from:
- the two R G1 groups connected to the same atom form a C 3-6 monocyclic hydrocarbon ring or a 3-6 membered monocyclic alicyclic heterocycle together with the atoms to which they are commonly connected;
- Cy A is phenyl, pyridyl, pyrimidinyl, pyrazolyl, imidazolyl, unsubstituted or optionally substituted with 1, 2, or 3 substituents independently selected from R12 , thiazolyl or isothiazolyl, wherein,
- Each R 12 is independently selected from: fluorine, chlorine, R G1 other than hydrogen, -OR G1 ;
- Cy A contains 1 R 12 selected from one of the following structures:
- Cy A contains 2 or 3 R 12 , wherein 1 R 12 is selected from one of the above structures, and the remaining R 12 is independently selected from: fluorine, chlorine, R G1 other than hydrogen, -OR G1 ;
- Each R G1 is independently selected from: hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 3-oxetanyl, and 3-methyl-3-azetidinyl.
- Cy B is selected from phenyl, naphthyl and 5-10 membered heteroaryl which are unsubstituted or optionally substituted with 1, 2, 3 or 4 groups independently selected from R 13 ;
- the 5-10-membered heteroaryl group has at least one ring-forming carbon atom and 1, 2, 3 or 4 ring-forming heteroatoms independently selected from N, O and S.
- Cy B is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 13 .
- Cy B is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2 or 3 substituents independently selected from R 13 , the heteroaryl group includes 1, 2 or 3 A ring-forming heteroatom selected from N, S.
- Cy B is phenyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazolyl, imidazolyl, optionally substituted with 1, 2, or 3 substituents independently selected from R13 , Thiazolyl, isothiazolyl, thienyl.
- Cy B is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 13 ; wherein, with phenyl or Two R 13 substituents attached to adjacent two ring atoms on a heteroaryl group and the two ring atoms together form unsubstituted or optionally by 1, 2, 3, 4 or 5 independently C 5-12 alicyclic hydrocarbon group or 5-12 membered alicyclic heterocyclic group substituted with a substituent selected from R 23 .
- Cy B is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2 or 3 substituents independently selected from R 13 ; wherein, with phenyl or heteroaryl, respectively Two R 13 substituents connected to adjacent two ring-forming atoms on the radical and said two ring-forming atoms together form unsubstituted or optionally substituted by 1, 2 or 3 independently selected from R 23 C 4-8 alicyclic hydrocarbon group or 4- to 8-membered alicyclic heterocyclic group substituted by group.
- Cy B is phenyl or 5-6 membered heteroaryl optionally substituted with 1, 2 or 3 substituents independently selected from R 13 ; wherein, with phenyl or heteroaryl, respectively Two R 13 substituents connected to adjacent two ring-forming atoms on the radical and said two ring-forming atoms together form unsubstituted or optionally substituted by 1, 2 or 3 independently selected from R 23 C 5-6 monocyclic alicyclic hydrocarbon group or 5-6 membered monocyclic alicyclic heterocyclic group;
- R 23 is optionally selected from fluoro, methyl, ethyl, isopropyl, cyclopropyl, ethylene and 3-oxetanyl.
- each R is independently selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 unsubstituted or optionally substituted with 1, 2 , 3, 4, 5 or 6 substituents independently selected from R 23 6 -alkynyl, 6-10-membered aryl, 5-10-membered heteroaryl, C 3-12 -membered cycloalkyl and 3-12-membered alicyclic heterocyclic group;
- each R is independently selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 unsubstituted or optionally substituted with 1, 2 , 3, 4, 5 or 6 substituents independently selected from R 23 6 -alkynyl, 6-10-membered aryl, 5-10-membered heteroaryl, C 3-10 -membered cycloalkyl and 3-10-membered alicyclic heterocyclic group;
- each R is independently selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 23 , 6-10-membered aryl, 5-10-membered heteroaryl, C 3-10 -membered cycloalkyl and 3-10-membered aliphatic heterocyclic group;
- each R is independently selected from:
- each R is independently selected from:
- each R is independently selected from:
- each R is independently selected from:
- each R is independently selected from:
- R a5 and R b5 are independently selected from hydrogen and C 1-6 alkyl, or, R a5 and R b5 connected to the same nitrogen atom and their The attached nitrogen atoms together form a 3- to 6-membered alicyclic heterocyclic group.
- each R 13 is independently selected from: halogen atom, cyano group, -OR a3 and -NR a3 R b3 ; wherein R a3 and R b3 are independently selected from:
- each R is independently selected from:
- R a3 and R b3 are independently selected from hydrogen, C 1-4 alkyl and C 3-6 cycloalkyl, or, R a3 and R b3 attached to the same nitrogen atom together form 3- 6-membered alicyclic group; R 23 is selected from C 1-6 alkyl and C 3-6 cycloalkyl.
- Cy B is selected from one of the following structures, the chemical bond terminal in the structural formula Indicates that it is connected to other atoms in the structure of formula (I) through this bond:
- R a3 and R b3 are independently selected from hydrogen and C 1-6 alkyl, or, R a3 and R b3 attached to two adjacent ring atoms and together with the two ring atoms to which they are attached A 5-6 membered monocyclic alicyclic hydrocarbon group or a 5-6 membered monocyclic alicyclic heterocyclic group is formed.
- R 1 is hydrogen
- Cy A is selected from phenyl, naphthyl, and 5-10-membered heteroaryl groups that are unsubstituted or optionally substituted with 1, 2, 3, or 4 groups independently selected from R 12 ; wherein, 5-10 A membered heteroaryl group has at least two ring-forming carbon atoms and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;
- R 12 is selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 22 , Phenyl, 5-6 membered heteroaryl, C 3-7 monocyclic cycloalkyl, C 6-10 bicyclic cycloalkyl, 3-7 membered monocyclic alicyclic heterocyclic group and 6-10 membered bicyclic cycloaliphatic ring base;
- R a2 , R b2 and R e2 are each independently selected from:
- R a2 and R b2 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3- to 8-membered lipid that is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 22 Heterocyclic group; wherein, the 3- to 8-membered alicyclic heterocyclic group contains 1 or 2 ring-forming heteroatoms, for example, only the above-mentioned nitrogen atom, or the above-mentioned nitrogen atom and any heteroatom selected from N, O and S;
- R c2 is selected from C 1-4 alkyl, C 2-3 alkenyl, phenyl, 5-6 membered unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 22 Heteroaryl, C 3-6 cycloalkyl and 3-6 membered alicyclic heterocyclic group;
- R 22 is selected from:
- R a4 , R b4 and R e4 are each independently selected from:
- R a4 and R b4 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3 to 6-membered unit that is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 32 Cycloaliphatic heterocyclic group or 6- to 7-membered bicyclic alicyclic heterocyclic group; wherein, the 3- to 6-membered monocyclic alicyclic heterocyclic group and the 6- to 7-membered bicyclic alicyclic heterocyclic group contain 1 or 2 ring-forming heteroatoms, For example, only the above-mentioned nitrogen atoms are contained, or the above-mentioned nitrogen atoms and any heteroatom selected from the group consisting of N, O and S;
- R c4 is selected from C 1-4 alkyl, C 2-3 alkenyl, C 3-6 monocyclic ring unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 32 Alkyl and 3-6 membered monocyclic alicyclic heterocyclic group;
- Cy B is selected from phenyl, naphthyl and 5-10-membered heteroaryl groups that are unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 13 ; wherein, 5-10 A membered heteroaryl group has at least two ring-forming carbon atoms and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S;
- R 13 is selected from:
- C 1-6 alkyl C 2-6 alkenyl, C 2-6 alkynyl, unsubstituted or optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 23 , Phenyl, 5-6 membered heteroaryl, C 3-7 monocyclic cycloalkyl, C 6-10 bicyclic cycloalkyl, 3-7 membered monocyclic alicyclic heterocyclic group and 6-10 membered bicyclic cycloaliphatic ring base;
- R a3 , R b3 and R e3 are each independently selected from:
- R a3 and R b3 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3- to 8-membered lipid that is unsubstituted or optionally substituted by 1, 2 or 3 substituents independently selected from R 23 Heterocyclic group; wherein, the 3- to 8-membered alicyclic heterocyclic group contains 1 or 2 ring-forming heteroatoms, for example, only the above-mentioned nitrogen atom, or the above-mentioned nitrogen atom and any heteroatom selected from N, O and S;
- R c3 is selected from C 1-4 alkyl, C 2-3 alkenyl, phenyl, 5-6 membered unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 23 Heteroaryl, C 3-6 cycloalkyl and 3-6 membered alicyclic heterocyclic group;
- R 23 is selected from:
- R a5 , R b5 and R e5 are each independently selected from:
- R a5 and R b5 attached to the same nitrogen atom together with the nitrogen atom to which they are attached form a 3 to 6-membered unit that is unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 33 Cycloaliphatic heterocyclic group or 6- to 7-membered bicyclic alicyclic heterocyclic group; wherein, the 3- to 6-membered monocyclic alicyclic heterocyclic group and the 6- to 7-membered bicyclic alicyclic heterocyclic group contain 1 or 2 ring-forming heteroatoms, For example, only the above-mentioned nitrogen atoms are contained, or the above-mentioned nitrogen atoms and any heteroatom selected from the group consisting of N, O and S;
- R c5 is selected from C 1-4 alkyl, C 2-3 alkenyl, C 3-6 monocyclic ring unsubstituted or optionally substituted with 1, 2 or 3 substituents independently selected from R 33 Alkyl and 3-6 membered monocyclic alicyclic heterocyclic group;
- R 33 is selected from oxo, halogen atoms, cyano, hydroxyl, -OR GA , amino, -NHR GA and -N(R GA ) 2 ;
- Each R GA is independently selected from:
- Two R GAs attached to the same nitrogen atom together with the attached nitrogen atom form a 4-6-membered monocyclic alicyclic heterocyclic group which is unsubstituted or optionally substituted by 1, 2 or 3 fluorine atoms; wherein, 4
- the ⁇ 6-membered monocyclic alicyclic heterocyclic group contains 1 or 2 ring-forming heteroatoms, for example, only the above-mentioned nitrogen atoms, or the above-mentioned nitrogen atoms and any heteroatom selected from N and O.
- Some embodiments of the present application provide a pharmaceutical composition
- a pharmaceutical composition comprising the above-mentioned compound of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isotope Constructs or prodrugs, and pharmaceutically acceptable carriers.
- the pharmaceutical combination can be prepared in a manner well known in the pharmaceutical art, and can be administered by various routes. Modes of administration can be topical (including transdermal, epidermal, ocular and mucosal, including intranasal, vaginal, and rectal delivery), pulmonary (eg, by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or nasal intradermal), oral or parenteral.
- topical including transdermal, epidermal, ocular and mucosal, including intranasal, vaginal, and rectal delivery
- pulmonary eg, by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or nasal intradermal
- oral or parenteral eg, by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or nasal intradermal
- the composition is suitable for parenteral administration.
- parenteral administration include intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection or infusion; or intracranial, such as intrathecal or intracerebroventricular administration.
- Parenteral administration can be in the form of a single bolus dose, or can be administered, for example, by a continuous infusion pump.
- compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- Conventional pharmaceutical carriers, aqueous, powdered or oily bases, thickeners and the like may be necessary or desirable.
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, as well as the above Use of a pharmaceutical combination in the prevention or treatment of diseases mediated by HPK1.
- Some embodiments of the present application provide methods of modulating (eg, inhibiting) HPK1 activity, comprising administering to a patient a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorphic form thereof Drugs, isotopic labels, isomers or prodrugs, and combinations of the above, to stimulate and/or enhance immunity in cancer or viral diseases.
- Some embodiments of the present application provide a method for preventing, ameliorating or treating a disease mediated by HPK1, comprising administering to a patient suffering from a disease mediated by HPK1 a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable amount thereof.
- a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable amount thereof Accepted salts, hydrates, solvates, active metabolites, polymorphs, isotopic labels, isomers or prodrugs, and combinations of the foregoing.
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, and Use of the above-mentioned drug combination in the treatment or improvement of benign or malignant tumors, myelodysplastic syndromes, and/or diseases caused by viruses.
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph , or the use of the above-mentioned pharmaceutical composition in the treatment or improvement of benign or malignant tumors.
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph , or the use of the above-mentioned pharmaceutical composition in the treatment or amelioration of a virus-induced disease.
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, and
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph , or the use of the above-mentioned pharmaceutical composition in the preparation of a medicament for treating or improving benign or malignant tumors.
- Some embodiments of the present application provide a compound of formula (I) above, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug thereof, or a pharmaceutically acceptable salt, hydrate, solvate, active metabolite, polymorph , or the use of the above-mentioned pharmaceutical composition in the preparation of a medicament for treating or ameliorating a virus-induced disease.
- the malignancy includes leukemia, lymphoma, multiple myeloma, lung cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, gastric cancer, colorectal cancer, intestinal leiomyosarcoma, breast cancer, ovarian cancer, cervical cancer, Endometrial cancer, vaginal cancer, malignant teratoma, pancreatic cancer, pancreatic ductal adenocarcinoma, nasopharyngeal cancer, oral cancer, laryngeal cancer, esophageal squamous cell carcinoma, thyroid cancer, kidney cancer, bladder cancer, malignant brain tumor, Rhabdomyosarcoma, osteosarcoma, chondrosarcoma, fibrosarcoma of bone, malignant thymoma, malignant peripheral nerve sheath tumor, prostate cancer, testicular cancer, penile cancer and other malignant tumors, as well as benign and malignant skin tumors (including but not limited to
- the tumor is a PGE2-producing tumor (eg, COX-2 overexpressing tumor) and/or adenosine-producing tumor (eg, CD39 and CD73 overexpressing tumor), such as colorectal cancer, breast cancer, pancreatic cancer , lung and ovarian cancer.
- a PGE2-producing tumor eg, COX-2 overexpressing tumor
- adenosine-producing tumor eg, CD39 and CD73 overexpressing tumor
- the virus includes hepatitis virus, human immunodeficiency virus, human papilloma virus, herpes simplex virus, measles virus, norovirus, boca virus, coxsackie virus, ebola virus, enterovirus, One or more of lymphocytic meningitis virus, influenza virus, SARS virus and novel coronavirus.
- a description or description of a group applies to all groups including this group, whether used alone or in combination with other terms.
- a description for an alkyl group applies to a C 1-6 alkyl group, a C 1-3 alkyl group, etc.
- a description or description for a C 1-6 alkyl group applies to a "C 1-6 alkoxy group", etc.
- the types of these substituents may be the same or different; for example, the Cy B group contains 2 R 13 substituents, these 2 R 13 Both may be methoxy groups, or one may be methoxy and the other may be methyl.
- halogen atom includes fluorine, chlorine, bromine, and iodine.
- Cmn group (where m and n are integers) designates a range inclusive of endpoints, indicating that the corresponding group contains mn carbon atoms.
- C 1-6 alkyl means an alkyl group having 1-6 carbon atoms
- C 2-6 alkenyl means an alkenyl group having 2-6 carbon atoms.
- n-membered (where n is an integer) generally describes the number of ring atoms in a moiety, where the number of ring atoms is n.
- m-n-membered indicates a range inclusive of the terminus, indicating that the corresponding ring structure contains m-n ring-forming atoms.
- piperidinyl is an example of a 6-membered heterocyclic group
- pyrazolyl is an example of a 5-membered heteroaryl group.
- substituted means that an atom or group of atoms formally replaces a hydrogen as a "substituent" attached to another group. Unless otherwise stated, the term “substituted” refers to any degree of substitution so long as the substitution is permissible. The choice of substituents is independent and the substitution can be at any chemically accessible position. It should be understood that substitution on a given atom is limited by valence. It will be appreciated that substitution at a given atom results in a chemically stable molecule. A single divalent substituent (eg, oxo) can replace two hydrogen atoms.
- Remainder of the compound refers to the portion of the complete molecular structure excluding the "substituents” mentioned.
- the remainder of the compound is attached to the substituent through one or more unsaturated valences.
- the remainder of the compound may contain one or more "points of attachment,” two or more of which may be on the same atom or on different atoms.
- alkyl refers to a straight or branched chain saturated hydrocarbyl group.
- An alkyl group is a group formed by the loss of one hydrogen atom from an alkane. Examples of alkyl groups are: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl , Neopentyl, 1-ethylpropyl, n-hexyl, 1,2,2-trimethylpropyl, etc.
- alkenyl refers to a straight or branched chain hydrocarbon group having one or more carbon-carbon double bonds.
- An alkenyl group is a group formed by the loss of one hydrogen atom from an alkene.
- alkenyl groups are: vinyl, 1-propenyl, 2-propenyl, allyl, 1-butenyl, 2-butenyl, (E)-but-2-en-1-yl, ( Z)-But-2-en-1-yl, 2-methyl-prop-1-en-1-yl, 1,3-butadien-1-yl, 1,3-butadiene-2- Base et al.
- alkynyl refers to a straight or branched chain hydrocarbon group having one or more carbon-carbon triple bonds. Alkynyl is a group formed by the loss of one hydrogen atom from an alkyne. Examples of alkynyl groups are: ethynyl, 1-propynyl, propargyl, 1-butynyl, but-2-yn-1-yl, but-3-yn-1-yl, but-3-ene -1-alkynyl, 3-methylpent-2-en-4-yn-1-yl and the like.
- alkylene refers to a divalent group formed by losing two hydrogen atoms on the carbon atom of an alkane at the same time. It can be that the two valences are concentrated on the same atom, or the two valences can be located on two separate valences. on an atom.
- the two connecting valences can be located on the same atom in the rest of the compound, or they can be located on two atoms in the rest of the compound respectively.
- 1,2-ethylene -CH2) CH 2 -
- butan-1,4-diyl butan-1,3-diyl, 2,2-dimethyl-propan-1,3-diyl and the like.
- alkoxy refers to a group of formula "-O-alkyl", wherein alkyl is as defined above. For example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, n-hexyloxy, and the like.
- alkylthio refers to a group of formula "-S-alkyl", wherein alkyl is as defined above. For example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, tert-butylthio, n-hexylthio and the like.
- alkylamino includes groups of formula "-NH-alkyl” and groups of formula "-N(alkyl) 2 ", wherein alkyl is as defined above.
- the group of formula "-NH-alkyl” can be, for example, methylamino, ethylamino, isopropylamino, n-hexylamino, etc.
- the group of formula "-N(alkyl) 2 " can be, for example, dimethylamino, diethyl Amino, methylethylamino, methylisopropylamino and ethyl-n-hexylamino, etc.
- cyano refers to a group of formula -C ⁇ N, which may also be written as -CN.
- hydroxymethyl refers to a group of formula -CH2OH .
- oxo refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to a carbon atom, or a sulfoxide or sulfone when attached to a heteroatom, or an N-oxide group, and the like.
- cycloalkyl and heterocyclyl groups can be optionally substituted with 1 or 2 oxo groups.
- cyclohydrocarbyl includes monocyclic or polycyclic alicyclic and aromatic hydrocarbyl groups.
- Monocyclic alicyclic hydrocarbon groups contain one hydrocarbon ring and include cyclized alkyl and alkenyl groups.
- Polycyclic alicyclic hydrocarbon groups contain two or more hydrocarbon rings, at least one alicyclic hydrocarbon ring (including cyclized alkyl and alkenyl groups), and other rings may be alicyclic hydrocarbon rings and/or aromatic hydrocarbon rings ; wherein any ring is connected to at least one other ring by spiro (two rings share one ring atom) or bridged ring (two rings share two or more ring atoms).
- a polycyclic hydrocarbon group is attached to the rest of the compound through a ring-forming carbon atom on the hydrocarbon ring.
- the cyclic hydrocarbon group is a saturated cyclic hydrocarbon group, also referred to as "cycloalkyl”.
- Cycloalkyloxy refers to a group of formula "-O-cycloalkyl", wherein cycloalkyl is as defined above. For example cyclopropyloxy.
- Cyclohydrocarbyl includes "cyclohydrocarbylene", that is, the cyclic hydrocarbyl group is connected to two points of attachment to the rest of the compound through two valences. They can be located on two carbon atoms of the cycloalkylene group respectively; the two connection points can be located on the same atom in the rest of the compound, or they can be located on two atoms in the rest of the compound respectively.
- cyclohydrocarbylene that is, the cyclic hydrocarbyl group is connected to two points of attachment to the rest of the compound through two valences. They can be located on two carbon atoms of the cycloalkylene group respectively; the two connection points can be located on the same atom in the rest of the compound, or they can be located on two atoms in the rest of the compound respectively.
- 1,1-cyclobutylene, 1,3-cyclobutylene, and the like are examples of 1,1-cyclobutylene, 1,3-cyclobutylene, and the like
- aryl refers to a monocyclic or polycyclic aromatic hydrocarbon group. For example: phenyl, naphthyl, etc.
- heterocyclyl refers to a monocyclic or polycyclic group having at least one heteroatom ring member selected from oxygen, nitrogen, sulfur and phosphorus.
- Polycyclic heterocyclyls contain two or more ring structures, wherein at least one ring structure has at least one heteroatom ring member selected from oxygen, nitrogen, sulfur and phosphorus, and other ring structures may have ring-forming heteroatoms or not. Ring-forming heteroatoms; wherein any ring is connected to at least one other ring by spiro (two rings sharing one ring atom) or bridged (two rings sharing two or more ring atoms).
- the heterocyclyl group can be attached to the remainder of the compound through an optional ring-forming carbon atom, and can also be attached to the remainder of the compound through an optional ring-forming heteroatom.
- any ring-forming carbon atom in a heterocyclyl group can be substituted with an oxo group to form a carbonyl group.
- any ring-forming nitrogen atom in a heterocyclyl group can be an N-oxide.
- any ring-forming nitrogen atom in a heterocyclyl group can be a quaternary ammonium ion.
- Heterocyclyl groups include aromatic heterocyclyl groups (ie, “heteroaryl groups”) and "aliphatic heterocyclyl groups.”
- Heteroaryl refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from oxygen, nitrogen and sulfur.
- a heteroaryl group can be attached to the remainder of the compound through an optional carbon atom, and can also be attached to the remainder of the compound through an optional heteroatom, provided the valence of the carbon atom or heteroatom allows it.
- any ring-forming carbon atom in the heteroaryl moiety can be substituted with an oxo group to form a carbonyl group.
- any ring-forming nitrogen atom in a heteroaryl moiety can be an N-oxide.
- any ring-forming nitrogen atom in the heteroaryl moiety can be a quaternary ammonium ion.
- pyrrolyl including pyrrol-1-yl, pyrrol-2-yl and pyrrol-3-yl
- pyrazolyl imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazole base, tetrazolyl, pyridyl, pyridin-2(1H)-on-1-yl, pyridin-4(1H)-on-1-yl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazin-3 (2H)-Keto-2-yl, 1,2,4-triazinyl, 1,3,5-triazinyl, indolyl, benzofuranyl, benzothienyl, indazolyl, benzoyl Imidazolyl,
- Aliphatic heterocyclic group includes monocyclic or polycyclic alicyclic heterocyclic groups.
- the monocyclic alicyclic heterocyclic group may contain no cyclic double bonds, or one or more cyclic double bonds.
- the polycyclic alicyclic heterocyclic group contains at least one alicyclic structure, and other rings may be alicyclic or aromatic rings; any ring structure in the polycyclic alicyclic heterocyclic group may not contain a cyclic double bond, or contain one or more A ring-forming double bond.
- azetidine oxetanyl, tetrahydropyrrolyl, tetrahydrofuranyl, 2-oxooxazolidinyl, piperidinyl, 3-oxopiperidinyl, piperazinyl, morpholinyl , azepanyl, 2-oxa-6-azaspiro[3.3]heptyl, 1,2,3,4-tetrahydroquinolinyl, etc.
- Heterocyclyl includes a heterocyclylene, that is, a heterocyclyl is connected to two points of attachment to the rest of the compound through two valences, and the two valences may be in the same ring-forming atom of the heterocyclylene. It can also be located on the two ring atoms of the heterocyclylene group; the two connection points can be located on the same atom in the rest of the compound, or can be located on two atoms in the rest of the compound. superior. For example, 1,1-(3-oxetanylene), 1,3-(2-azacyclopentylene), and the like.
- paracyclic refers to a bridged ring system formed by two rings sharing two adjacent ring-forming atoms; the two rings may be saturated alicyclic, unsaturated alicyclic or aromatic rings, and the two Adjacent ring-forming atoms are optionally carbon atoms or heteroatoms.
- n-membered oxaalkylene refers to a divalent group formed by replacing one or more carbon atoms in the main chain of an n-membered alkylene with an oxygen atom.
- 2-oxa-1,3-propylene (-CH2OCH2-) is a 3-membered oxaalkylene
- 2-oxa-1,4-butylene (-CH2OCH2CH2-) is an example of a 4-membered oxaalkylene and the like.
- alkylene group in which only branched carbon atoms are replaced by oxygen atoms should not be considered "oxaalkylene"; for example, in 2-methyl-1,3-propylene, the branched-chain methyl group is replaced by oxygen.
- the group (-CH2CH(OH)CH2-) should be regarded as 2-hydroxy substituted 1,3-propylene.
- n-membered azaalkylene refers to a divalent group formed by replacing one or more carbon atoms in the main chain of an n-membered alkylene chain with a nitrogen atom, and the two valences described may be in the compound On the same atom as the rest of the compound, or on two separate atoms from the rest of the compound; for example, 2-aza-1,3-propylene (-CH2NHCH2-) is a 3-membered azaalkylene
- aza-1,2-ethylene (-CH2NH-) is an example of a 2-membered azaalkylene, and the like.
- alkylene group in which only branched carbon atoms are substituted with nitrogen atoms should not be considered "azaalkylene"; for example, in 2-methyl-1,3-propylene, the branched-chain methyl group is substituted with nitrogen.
- the group (-CH2CH(NH2)CH2-) should be regarded as 2-amino substituted 1,3-propylene.
- isomers refers to isomers that result from different arrangements of atoms in a molecule in space.
- Stepoisomers of the compounds described herein refers to all stereoisomers. For example, when the compound has asymmetric carbon atoms, enantiomers and diastereomers are produced; when the compound has carbon-carbon double bonds, carbon-nitrogen double bonds, or ring structures, cis-isomers are produced. anti-isomer.
- the compounds described herein include all isomers thereof, such as optically active isomers, geometric isomers, rotational isomers, tautomers, stably existing conformational isomers, and the like; and It may exist as a mixture of isomers or as isolated isomers.
- Resolution of racemic mixtures of compounds can be carried out by any of a number of methods known in the art.
- One method involves fractional recrystallization using a chiral resolving acid that is an optically active salt-forming organic acid.
- Suitable resolving agents for fractional recrystallization can be optically active acids such as D-tartaric acid, L-tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, -camphorsulfonic acid, etc.;
- Suitable resolving agents for fractional recrystallization include, for example, -methylbenzylamine, 2-phenylglycinol, cyclohexylethylamine and the like in stereoisomerically pure form.
- Methods for resolution of racemic mixtures also include, for example, the separation of diastereomers by reaction with appropriate optically active species such as chiral alcohols or Mosher's acid chlorides to convert to diastereomers And conversion (such as hydrolysis) to the corresponding single optical isomer to implement. For example, it is carried out by elution on a chromatographic column packed with an optically active resolving agent. Suitable chromatographic column and elution solvent compositions can be determined by those skilled in the art.
- isotopic label refers to a compound of the present application in which one or more of its constituent atoms have been replaced by a particular isotopic atom thereof.
- the isotopes in the compounds of the present application may include various isotopes of elements such as H, C, N, O, F, P, S, Cl and I, such as 2 H, 3 H, 13 C, 14 C, 15 N , 17 O, 18 O, 18 F, 30 P, 32 P, 35 S, 36 S, 123 I, 124 I and 125 I, etc.
- This application includes various isotopically labeled compounds as defined.
- radioactive isotopes such as3H and14C
- non - radioactive isotopes such as2H and13C
- isotopically-labeled compounds are suitable for metabolic studies ( using14C ); reaction kinetic studies (using eg2H or3H ); detection or imaging techniques such as positron emission tomography (PET) or single photon radiation Computed tomography (SPECT), including drug or substrate tissue distribution analysis; or radiotherapy for patients, etc.
- PET positron emission tomography
- SPECT single photon radiation Computed tomography
- 18F compounds may be particularly desirable for PET or SPECT studies.
- Isotopically-labeled compounds of formula (I) can generally be substituted by conventional techniques known to those skilled in the art or by methods analogous to those described in the accompanying examples and preparations using an appropriate isotopically-labeled reagent in place of the previous prepared using unlabeled reagents.
- substitution with heavier isotopes may yield certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dose requirements or improved therapeutic index, and thus in some situation may be preferred.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms, which are within the scope of sound medical judgment, suitable for use in contact with human and animal tissue without excessive of toxicity, irritation, allergic reactions or other problems or complications commensurate with a reasonable benefit/risk ratio.
- “Pharmaceutically acceptable salts” refers to salts that retain the biological utility and properties of the compounds of the present application and generally have no biological or otherwise undesirable effects. In many cases, the compounds of the present application are capable of forming acid and/or base addition salts via the presence of amino and/or carboxyl groups or the like.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- All compounds and pharmaceutically acceptable salts thereof can be found (eg, hydrates and solvates) with other substances (eg, solvents, including water and other solvents, etc.) or can be isolated.
- the compounds described herein and salts thereof can exist in various forms, including hydrates and solvates.
- Hydrates and solvates of compounds and salts thereof described herein include those in which water and solvents may be isotopically substituted, eg, D2O , methanol- d3 , methanol- d4 , acetone- d 6 , DMSO-d 6 .
- the presence of hydrates and solvates can be identified by those skilled in the art using means such as nuclear magnetic resonance (NMR).
- polymorph refers to compounds of the present application that exist in different crystal lattice forms, as well as in amorphous forms. Polymorphs of the compounds of the present application and salts thereof also include mixtures of various lattice forms, as well as mixtures of one or several lattice forms and amorphous forms. The presence of polymorphs can be identified by those skilled in the art using means such as X-ray diffraction.
- references to compounds and salts thereof in this specification are to be understood to encompass any solid state form of the compounds.
- active metabolite refers to an active derivative of a compound that is formed when the compound is metabolized.
- “Pharmaceutically acceptable prodrug” refers to any pharmaceutically acceptable ester, ester salt, amide or other derivative of a compound of the present application which, upon administration to a recipient, is capable of providing the compound of the present application, directly or indirectly or its pharmacologically active metabolites or residues.
- Particularly preferred derivatives or prodrugs are those compounds that, when administered to a patient, increase the bioavailability of the compounds of the present application (eg, make orally administered compounds more readily absorbed into the bloodstream), or promote the delivery of the parent compound to biological organs or those compounds delivered at the site of action.
- composition refers to a biologically active compound optionally in admixture with at least one pharmaceutically acceptable chemical component or agent, which is a “carrier” that facilitates For introducing compounds into cells or tissues, include but are not limited to stabilizers, diluents, suspending agents, thickening agents and/or excipients.
- compositions include, but are not limited to, the following forms: tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (solid or dissolved in liquid vehicles), ointments, soft and hard gelatin capsules, suppositories, transdermal patches, sterile injectable solutions and sterile packaged powders, among others.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (eg, antibacterial, antifungal), isotonic agents, as known to those skilled in the art agents, absorption delaying agents, salts, preservatives, pharmaceutical stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, and the like, and combinations thereof. Unless any conventional carrier is incompatible with the active ingredient, its use in therapeutic or pharmaceutical compositions is contemplated.
- a “therapeutically effective amount” refers to the amount of a compound of the present application that induces a biological or medical response in a subject, such as reducing or inhibiting enzyme or protein activity or ameliorating symptoms, alleviating a condition, slowing or delaying disease progression, or preventing disease, etc. .
- “Individual” or “patient” refers to an individual, including mammals and non-mammals, suffering from a disease, disorder, condition, or the like.
- mammals include, but are not limited to, any member of the class Mammalia: humans; non-human primates (eg, chimpanzees and other apes and monkeys); livestock, such as cattle, horses, sheep, goats, pigs; other domesticated Animals, such as rabbits, dogs, and cats; laboratory animals, including rodents, such as rats, mice, and guinea pigs, and the like.
- non-mammals include, but are not limited to, birds, fish, and the like.
- the compounds of the present application and their salts can be prepared using known organic synthesis techniques and can be prepared according to any of a number of possible synthetic routes such as those in the schemes below.
- the reactions used to prepare the compounds of the present application can be carried out in suitable solvents.
- suitable solvents may be substantially unreactive with the starting materials (reactants), intermediates or products at temperatures at which the reaction is carried out (eg, temperatures that may range from the solvent's freezing temperature to the solvent's boiling temperature).
- a given reaction can be carried out in one solvent or a mixture of solvents. Depending on the particular reaction step, one skilled in the art can select an appropriate solvent for the particular reaction step.
- the preparation of the compounds of the present application can involve the protection and deprotection of various chemical groups.
- the need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by those skilled in the art.
- Various compounds of formula (I) can be prepared using the methods set forth in Scheme 1 .
- the compound of formula 1-1 is formed by a diazotization and coupling reaction to form the compound of formula 1-2.
- Compounds of formula 1-2 form compounds of formula 1-3 by ring closure reactions such as thermal ring closure, as well as acid or base catalyzed ring closure reactions.
- Compounds of formula 1-3 are amidated to form compounds of formula 1-4.
- Compounds of formula 1-4 are formed by chlorination and dehydration (eg, chlorination and dehydration in the presence of phosphorus oxychloride) to form compounds of formula 1-5.
- Compounds of formula 1-5 are ring-closed by condensation with hydrazine (or hydrazine hydrate) to form compounds of formula 1-6.
- Compounds of formula 1-6 undergo Sandmeyer or similar reactions to form halogenated (eg, chloro, bromo, or iodo) compounds of formula 1-7.
- the NH group of the pyrazole is protected with a suitable protecting group to form compounds of formula 1-8.
- Compounds of formula 1-8 are formed by various cross-coupling reactions (eg, Suzuki reaction, Stille reaction, etc.) to form compounds of formula 1-9.
- the compound of formula (I) is formed by deprotection.
- the compounds of formula 1-7 can be directly passed through various cross-coupling reactions (eg Suzuki reaction, Stille reaction, etc.), and subsequent reactions (such as reductive amination, carboxylamine condensation, etc.) to form the desired compound of formula (I).
- various cross-coupling reactions eg Suzuki reaction, Stille reaction, etc.
- subsequent reactions such as reductive amination, carboxylamine condensation, etc.
- various compounds of formula (I) can be prepared using the methods set forth in Scheme 2.
- the compound of formula 1-1 is formed by the same method as shown in Scheme 1 to form the compound of formula 1-3.
- Compounds of formula 1-3 are chlorinated to form compounds of formula 2-4.
- Compounds of formula 2-4 are condensed with excess hydrazine (or hydrazine hydrate) to form compounds of formula 2-5A; or compounds of formula 2-4 are condensed with an equivalent of hydrazine (or hydrazine hydrate) to form compounds of formula 2-5B.
- Compounds of formula 2-5A or 2-5B can be formed by ring closure reactions (eg, thermal ring closure, and acid- or base-catalyzed ring closure reactions) to form compounds of formula 2-6.
- Compounds of formula 2-6 are formed by halogenation (eg, chloro, bromo, etc.) to form compounds of formula 1-7.
- Compounds of formula 1-7 can be formed in a manner as shown in Scheme 1 to form the desired compound of formula (I).
- Scheme 2 is subdivided into Scheme 2A and Scheme 2B according to different compounds of formula 2-5A or formula 2-5B through intermediates.
- various compounds of formula (I) can be prepared using the methods set forth in Scheme 3A.
- a carboxylic acid derivative compound of formula 3-1a (wherein X is a halogen or a halogen-like, such as bromine, iodine, etc.; L1 is an aromatic or heteroaromatic ring; LG is a leaving group such as halogen , alkoxy, -N(Me)OMe, etc.) by condensation to form compounds of formula 3-2a.
- Compounds of formula 1-1 are formed by diazotization and coupling with compounds of formula 3-2a to form compounds of formula 3-3.
- the compound of formula 3-3 is formed into compound of formula 3-4 by a ring closure reaction.
- Compounds of formula 3-4 are formed by condensation with hydrazine (or hydrazine hydrate) to form compounds of formula 3-5A.
- Compounds of formula 3-5A are formed by protecting the NH group of the pyrazole with an appropriate protecting group to form compounds of formula 3-6.
- the halogens or halogen-like compounds in the compounds of formula 3-6 undergo various cross-coupling reactions (eg Suzuki reaction, Stille reaction, Buchwald-Hartwig amination) isocoupling reaction) to form compounds of formula 1-9.
- the compound of formula (I) is formed by deprotection.
- the compound of formula 3-5A can be directly processed through various cross-coupling reactions (eg Suzuki reaction, Stille reaction, Buchwald-Hartwig amination) Hartwig amination) etc. coupling reaction) to form the desired compound of formula (I).
- various cross-coupling reactions eg Suzuki reaction, Stille reaction, Buchwald-Hartwig amination) Hartwig amination
- various compounds of formula (I) can be prepared by the methods set forth in Scheme 3B.
- a compound of formula 3-4 is condensed with a substituted hydrazine, a compound of formula 3-5B can be formed.
- the halogens or halogen-like compounds in the compounds of formula 3-5B undergo various cross-coupling reactions (eg Suzuki reaction, Stille reaction, Buchwald-Hartwig amination) isocoupling reaction) to form compounds of formula 1-9B.
- the compound of formula (I) is formed by deprotection.
- various compounds of formula (I) can be prepared using the methods set forth in Scheme 4.
- a carboxylic acid derivative compound of formula 3-1a (wherein X is a halogen or a halogen-like, such as bromine, iodine, etc.; L1 is an aromatic or heteroaromatic ring; LG is a leaving group such as halogen , alkoxy, -N(Me)OMe, etc.) through condensation to form the compound of formula 4-3; or the aldehyde compound of formula 4-1 through addition reaction and oxidation reaction (such as using Dess-Martin oxidant) to form formula 4- 3 compounds.
- Compounds of formula 1-1 are diazotized and coupled with compounds of formula 4-3 to form compounds of formula 4-4.
- Compounds of formula 4-4 are subjected to ring closure reaction to generate compounds of formula 3-4.
- Compounds of formula 3-4 can form the desired compounds of formula (I) in a manner as shown in Schemes 3A or 3B.
- the reaction can be monitored according to any suitable method known in the art, such as nuclear magnetic resonance spectroscopy (NMR), infrared spectroscopy (IR), spectrophotometry (eg, UV-Vis spectroscopy), liquid mass spectrometry (LC-MS), mass spectrometry , high performance liquid chromatography, thin layer chromatography (or thin layer chromatography) and so on.
- NMR nuclear magnetic resonance spectroscopy
- IR infrared spectroscopy
- LC-MS liquid mass spectrometry
- mass spectrometry high performance liquid chromatography
- thin layer chromatography or thin layer chromatography
- the product can be purified by any suitable method known in the art, such as column chromatography (normal or reverse phase), preparative thin layer chromatography, beating, recrystallization, and the like.
- Normal phase column chromatography usually uses Qingdao Ocean 100-200 mesh silica gel as the carrier.
- TLC Thin-layer chromatography
- pre-TLC preparative thin-layer chromatography
- the structures of the compounds of the examples of the present application were determined by nuclear magnetic resonance spectroscopy (NMR) or/and liquid chromatography-mass spectrometry (LC-MS).
- the nuclear magnetic resonance spectrum was measured by Bruker AVANCE-400 nuclear magnetic resonance instrument, and the measuring solvent was usually deuterated dimethyl sulfoxide (DMSO-d 6 ) or deuterated chloroform (CDCl 3 ).
- NMR chemical shifts ([delta]) are given in parts per million (ppm) and the internal standard is tetramethylsilane (TMS).
- LC-MS was performed on an Agilent 1100 series liquid chromatograph and a Bruker HCT-Ultra ion trap mass spectrometer.
- Step 2 Preparation of methyl 1-(2-fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 3 Preparation of 1-(2-Fluoro-6-methylphenyl)-4-hydroxy-6-oxo-1,6-dihydropyridazine-3-carboxamide
- Step 4 Preparation of 4-chloro-1-(2-fluoro-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carbonitrile
- Step 5 Preparation of 3-amino-5-(2-fluoro-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one
- This compound was prepared according to the procedure described in Example 1 (step 1) using 2-methoxy-6-methylaniline instead of 2-fluoro-6-methylaniline as the starting material. Yield 79%.
- Step 2 Preparation of methyl 4-hydroxy-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 3 Preparation of methyl 4-chloro-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 4 Preparation of 4-hydrazino-1-(2-methoxy-6-methylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid hydrazide
- Step 6 Preparation of 3-chloro-5-(2-methoxy-6-methylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one
- Step 3 Preparation of methyl 5-(4-bromophenyl)-4-(2-(2,4-dimethoxyphenyl)hydrazino)-3,5-dioxopentanoate
- 2,4-Dimethoxyaniline 200 mg, 1.31 mmol was mixed with water (1.6 mL), stirred in an ice bath and aqueous concentrated hydrochloric acid (0.8 mL) and sodium nitrite (90 mg, 1.31 mmol) were added dropwise sequentially (1.2 mL), after the dropwise addition was completed, the solution was kept and stirred for 0.5 hours to obtain a diazonium salt solution.
- the aqueous phase was adjusted to pH 4-5 with saturated citric acid solution, extracted twice with ethyl acetate (20 mL ⁇ 2), the organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to dryness under reduced pressure to give 6-(4-bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one (67 mg) as a yellow solid , 0.16 mmol). Yield 72%.
- Step 5 Reduction of 3-(4-bromophenyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one preparation
- 6-(4-Bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one (47 mg, 0.11 mmol) was dissolved in n-butanol (2 mL), added glacial acetic acid (31 uL, 0.55 mmol) and hydrazine hydrate (33 uL, 0.55 mmol), heated to 120° C. under nitrogen protection, stirred for 15 hours, the reaction was completed. The reaction solution was cooled to room temperature, and a solid was precipitated, which was filtered.
- reaction solution was cooled to room temperature, concentrated to dryness, and the residue was purified by thin layer chromatography (dichloromethane/methanol: 10/1) to obtain crude product, which was slurried with methanol (0.5 mL) at room temperature to obtain yellow solid compound 4 (3.4 mg, 0.0077 mmol). Yield 33%.
- Step 1 Preparation of 2-methoxy-6-fluorophenyldiazonium tetrafluoroborate
- Step 2 6-(2-(4-Bromophenyl)-1-(2-(2-fluoro-6-methoxyphenyl)hydrazino)-2-oxoethyl)-2,2- Preparation of dimethyl-4H-1,3-dioxin-4-one
- 6-(2-(4-Bromophenyl)-2-oxoethyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (694 mg, 2.13 mmol) was dissolved in In ethanol (20 mL), sodium acetate (506 mg, 6.16 mmol) was added and cooled to -5°C.
- a solution of 2-methoxy-6-fluorophenyldiazonium tetrafluoroborate (539 mg, 2.25 mmol) in acetonitrile (3 mL) was added dropwise and stirred for 20 minutes.
- the reaction solution was poured into a mixed solution of ethyl acetate and an aqueous ammonium chloride solution, and the solution was separated.
- Step 4 3-(4-Bromophenyl)-5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one preparation
- Step 1 3-(4-Bromophenyl)-1-(2,4-dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-1H-pyrazolo[4 Preparation of ,3-c]pyridazin-6(5H)-one
- 6-(4-Bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one according to the procedure described in Example 4 (step 4) preparation.
- 6-(4-Bromobenzoyl)-2-(2,4-dimethoxyphenyl)-5-hydroxypyridazin-3(2H)-one (840 mg, 1.95 mmol)
- 2,4- Dimethoxyphenylhydrazine dihydrochloride (646 mg, 2.53 mmol)
- anhydrous sodium acetate (479 mg, 5.84 mmol) were added with n-butanol (10 mL), heated to 100° C., and stirred for 1 hour.
- Step 2 1-(2,4-Dimethoxybenzyl)-5-(2,4-dimethoxyphenyl)-3-(4-(4-methylpiperazin-1-yl) Preparation of Phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one
- reaction solution was diluted with dichloromethane, washed with water and separated. The organic phase was dried and concentrated. The residue was purified by column chromatography (dichloromethane/methanol: 100/1 to 30/1) to give 1-(2,4-dimethoxybenzyl)-5-(2,4-dimethylene) as an orange-red solid oxyphenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one (203 mg , 0.34 mmol), yield 44%.
- This compound was prepared according to the procedure described in Example 2 (step 1) using 2-fluoro-6-methoxyaniline instead of 2-methoxy-6-methylaniline as the starting material. Yield 94%.
- Step 2 Preparation of methyl 4-hydroxy-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 3 Preparation of methyl 4-chloro-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 4 Preparation of methyl 4-hydrazino-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Methyl 4-chloro-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (4.0 g, 12.8 mmol, 1.0 eq ) and DIPEA (8.4 mL, 51.3 mmol, 4.0 eq) were suspended in ethanol (40 mL), and a solution of 98% hydrazine hydrate (785 mg, 15.4 mmol, 1.2 eq) in ethanol (40 mL) was added dropwise at room temperature. After the dropwise addition, the mixture was stirred at room temperature for 4 hours.
- reaction solution was diluted with water (150 mL) and extracted three times with ethyl acetate. The organic phases were combined, washed with brine, dried, filtered and concentrated to dryness. The residue was purified by column chromatography (dichloromethane/methanol: 100/1) to give 4-hydrazino-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6 as a yellow solid - Methyl dihydropyridazine-3-carboxylate (2.3 g), 59% yield.
- Step 5 Preparation of 5-(2-Fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazine-3,6(2H,5H)-dione
- Methyl 4-hydrazino-1-(2-fluoro-6-methoxyphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (1.6 g, 5.19 mmol, 1.0 eq) was dissolved in a mixed solvent of methanol (15 mL) and tetrahydrofuran (15 mL), an aqueous solution (15 mL) of lithium hydroxide monohydrate (436 mg, 10.38 mmol, 2.0 eq) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated to dryness.
- Step 6 Preparation of 3-chloro-5-(2-fluoro-6-methoxyphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one
- Step 1 Preparation of tert-butyl (2-fluoro-6-cyclopropylphenyl)carbamate
- This compound was prepared according to the procedure described in Example 29 (step 4) using tert-butyl (2-fluoro-6-cyclopropylphenyl)carbamate as starting material in 87% yield.
- Step 3 Preparation of 2-Cyclopropyl-6-fluorophenyldiazonium tetrafluoroborate
- Step 4 Preparation of methyl 5-(4-bromophenyl)-4-(2-(2-fluoro-6-cyclopropylphenyl)hydrazino)-3,5-dioxopentanoate
- reaction solution was concentrated under reduced pressure, diluted with water (60 mL), extracted with ethyl acetate (20 mL*3), and the organic phases were combined. The organic phase was washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered with suction, and concentrated to dryness. The residue was purified by column chromatography (petroleum ether/ethyl acetate: 15/1) to give 5-(4-bromophenyl)-4-(2-(2-fluoro-6-cyclopropylphenyl) as a yellow solid hydrazino)-3,5-dioxopentanoate methyl ester (435 mg, 0.94 mmol), 61% yield. .
- Step 5 Preparation of 6-(4-Bromobenzoyl)-2-(2-fluoro-6-cyclopropylphenyl)-5-hydroxypyridazin-3(2H)-one
- Step 6 3-(4-Bromophenyl)-5-(2-fluoro-6-cyclopropylphenyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one preparation
- Step 7 3-(4-Bromophenyl)-5-(2-cyclopropyl-6-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)-1H- Preparation of Pyrazolo[4,3-c]pyridazin-6(5H)-one
- reaction solution was poured into water (50 mL), extracted three times with ethyl acetate (15 mL*3), and the organic phases were combined.
- the organic phase was washed with saturated brine (50 mL*3), dried over anhydrous sodium sulfate, filtered with suction, and concentrated to dryness.
- Step 8 5-(2-Cyclopropyl-6-fluorophenyl)-3-(4-(4-methylpiperazin-1-yl)phenyl)-1-(2-(trimethylsilane) Preparation of yl)ethoxymethyl)-1H-pyrazolo[4,3-c]pyridazin-6(5H)-one
- reaction solution was poured into saturated aqueous ammonium chloride solution (60 mL), and extracted three times with ethyl acetate (20 mL*3), and the organic phases were combined.
- the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered with suction, and concentrated to dryness.
- the kinase activity of HPK1 is manifested as autophosphorylation activity and phosphorylation of downstream substrates.
- additional substrates are not required, and ATP is consumed to generate ADP.
- the amount of the product is detected by ADP-Glo reagent and luminescence method to reflect Kinase activity.
- Test substance compounds prepared in the examples of this application.
- Human Jurkat-E6-1 cells were incubated with different concentrations of test compounds for 30 min in a humidified incubator at 37°C and 5% CO2 . Transfer cells to cell culture plates pre-coated with anti-human CD3 antibody, then add soluble anti-human CD28 antibody and stimulate cells for 24 h in a humidified incubator at 37 °C and 5% CO .
- the cell culture medium was collected by centrifugation, and the cell culture sample was transferred to a 96-well transparent microtiter plate (Thermo) pre-coated with anti-human IL-2 antibody, incubated at room temperature for 2 hours, and gently shaken, washed with washing buffer Wash the ELISA plate 4 times, and then follow the ELISA MAX Deluxe Set Human IL-2 (BioLegend) kit operation procedure, use a microplate reader (Molecular Device, i3X) to read the OD value. The best standard curve was selected by the microplate reader application software, and the corresponding concentration was calculated according to the OD value of the standard. Results are expressed as a percentage of the amount of IL-2 secreted by compound-treated/DMSO-treated cells.
- Table 2 shows that, compared with Jurkat cells treated with DMSO as a blank control group, the compounds of the examples of the present application have a significant promoting effect on the secretion of cytokine IL-2 by Jurkat cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
名称 | 储液浓度 | 体积 | 终浓度 |
Tris | 1M(25X) | 240μL | 40mM |
MgCl 2 | 1M(50X) | 120μL | 20mM |
BSA | 7.5%(75X) | 80μL | 0.1% |
DTT | 1M(500X) | 3μL | 0.5mM |
ddH 2O | 5557μL |
化合物 | IC50 | 化合物 | IC50 |
化合物1 | +++ | 化合物123 | +++ |
化合物2 | ++ | 化合物124 | +++ |
化合物3 | +++ | 化合物125 | +++ |
化合物4 | +++ | 化合物126 | +++ |
化合物5 | ++ | 化合物127 | +++ |
化合物6 | +++ | 化合物128 | +++ |
化合物7 | ++ | 化合物129 | +++ |
化合物8 | +++ | 化合物130 | +++ |
化合物9 | +++ | 化合物131 | ++ |
化合物10 | +++ | 化合物132 | +++ |
化合物11 | ++ | 化合物133 | +++ |
化合物12 | + | 化合物134 | +++ |
化合物13 | ++ | 化合物135 | +++ |
化合物14 | ++ | 化合物136 | +++ |
化合物15 | + | 化合物137 | +++ |
化合物16 | + | 化合物138 | +++ |
化合物17 | + | 化合物139 | +++ |
化合物19 | + | 化合物140 | +++ |
化合物20 | ++ | 化合物141 | +++ |
化合物21 | ++ | 化合物142 | +++ |
化合物23 | +++ | 化合物143 | +++ |
化合物24 | +++ | 化合物144 | +++ |
化合物25 | ++ | 化合物145 | +++ |
化合物26 | + | 化合物146 | +++ |
化合物27 | +++ | 化合物147 | +++ |
化合物28 | +++ | 化合物148 | +++ |
化合物29 | +++ | 化合物149 | + |
化合物32 | ++ | 化合物150 | + |
化合物33 | +++ | 化合物151 | ++ |
化合物34 | +++ | 化合物152 | ++ |
化合物42 | +++ | 化合物153 | ++ |
化合物47 | + | 化合物154 | ++ |
化合物48 | ++ | 化合物155 | ++ |
化合物55 | ++ | 化合物156 | +++ |
化合物58 | ++ | 化合物157 | +++ |
化合物61 | +++ | 化合物158 | ++ |
化合物72 | ++ | 化合物159 | +++ |
化合物73 | +++ | 化合物160 | +++ |
化合物74 | +++ | 化合物161 | +++ |
化合物75 | + | 化合物162 | +++ |
化合物76 | +++ | 化合物163 | ++ |
化合物77 | +++ | 化合物164 | ++ |
化合物78 | ++ | 化合物165 | ++ |
化合物79 | +++ | 化合物166 | ++ |
化合物80 | +++ | 化合物167 | ++ |
化合物81 | +++ | 化合物168 | ++ |
化合物82 | +++ | 化合物169 | ++ |
化合物83 | +++ | 化合物170 | +++ |
化合物84 | ++ | 化合物171 | ++ |
化合物85 | +++ | 化合物172 | ++ |
化合物86 | +++ | 化合物173 | ++ |
化合物87 | +++ | 化合物174 | ++ |
化合物88 | ++ | 化合物175 | ++ |
化合物89 | +++ | 化合物176 | +++ |
化合物90 | +++ | 化合物177 | +++ |
化合物91 | +++ | 化合物178 | ++ |
化合物92 | +++ | 化合物179 | ++ |
化合物93 | +++ | 化合物180 | +++ |
化合物94 | +++ | 化合物181 | ++ |
化合物95 | ++ | 化合物182 | ++ |
化合物96 | ++ | 化合物183 | + |
化合物97 | ++ | 化合物184 | ++ |
化合物98 | +++ | 化合物185 | + |
化合物99 | ++ | 化合物186 | + |
化合物100 | ++ | 化合物187 | ++ |
化合物101 | +++ | 化合物188 | ++ |
化合物102 | ++ | 化合物189 | ++ |
化合物103 | +++ | 化合物190 | ++ |
化合物104 | ++ | 化合物191 | ++ |
化合物105 | +++ | 化合物193 | +++ |
化合物106 | +++ | 化合物194 | +++ |
化合物107 | +++ | 化合物195 | ++ |
化合物108 | ++ | 化合物196 | ++ |
化合物109 | +++ | 化合物197 | +++ |
化合物110 | ++ | 化合物198 | +++ |
化合物111 | +++ | 化合物199 | +++ |
化合物112 | +++ | 化合物200 | +++ |
化合物113 | +++ | 化合物201 | +++ |
化合物114 | +++ | 化合物202 | +++ |
化合物115 | +++ | 化合物203 | +++ |
化合物116 | +++ | 化合物204 | +++ |
化合物117 | +++ | 化合物205 | +++ |
化合物118 | +++ | 化合物206 | ++ |
化合物119 | +++ | 化合物207 | + |
化合物120 | +++ | 化合物208 | +++ |
化合物121 | +++ | 化合物209 | ++ |
化合物122 | +++ | 化合物210 | +++ |
Claims (19)
- 一种式(I)化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1选自:1)氢、卤族原子、氰基、-C(=O)NR aR b、-OR a和-NR aR b;2)未被取代或任选地被1、2、3或4个独立地选自R 11的取代基取代的C 1-6烷基、C 2-4烯基、C 2-4炔基、C 3-8环烷基和3~8元脂杂环基;R a和R b各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R 11的取代基取代的C 1-6烷基、C 2-4烯基、C 2-4炔基、C 3-6单环环烷基和3~6元单环脂杂环基;或者,连接于同一氮原子的R a和R b与它们所连接的氮原子一起形成未被取代或任选地被1、2或3个独立地选自R 11的取代基取代的3~6元单环脂杂环基;R 11选自氟、氯、氰基、C 1-3烷基和羟基;Cy A选自未被取代或任选地被1、2、3、4或5个独立地选自R 12的取代基取代的6~10元芳基或5~10元杂芳基;R 12选自:1)氧代基、卤族原子、氰基、-C(=O)R a2、-C(=O)OR a2、-C(=O)NR a2R b2、-C(=NR d2)NR a2R b2、-OR a2、-OC(=O)R a2、-OC(=O)OR c2、-OC(=O)NR a2R b2、-SR a2、-S(=O)R c2、-S(=O) 2R c2、磺酸基、-S(=O)NR a2R b2、-S(=O) 2NR a2R b2、-S(=O)(=NR d2)R c2、-NR a2R b2、-NR a2C(=O)R b2、-NR a2C(=O)OR c2、-NR e2C(=O)NR a2R b2、-NR e2C(=NR d2)NR a2R b2、-NR a2S(=O) 2R c2、-NR e2S(=O) 2NR a2R b2、硝基、-PR c2R f2、-P(=O)R c2R f2和膦酸基;2)未被取代或任选地被1、2、3、4、5或6个独立地选自R 22的取代基取代的C 1-6烷基、C 2-6烯基、C 2-6炔基、6~10元芳基、5~10元杂芳基、C 3-12环烷基和3~12元脂杂环基;3)分别与Cy A的芳基或杂芳基上相邻的两个成环原子相连的两个R 12取代基和与所述两个成环原子一起形成未被取代或任选地被1、2、3、4、5或6个独立地选自R 22的取代基取代的C 5-12脂环烃基或5~12元脂杂环基;R a2、R b2和R e2各自独立地选自:1)氢;2)未被取代或任选地被1、2、3、4、5或6个独立地选自R 22的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-12环烷基和3~12元脂杂环基;或者,连接于同一氮原子的R a2和R b2与所述氮原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 22的取代基取代的3~12元脂杂环基;R c2和R f2各自独立地选自:未被取代或任选地被1、2、3、4或5个独立地选自R 22的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-12环烷基和3~12元脂杂环基;或者,连接于同一磷原子的R c2和R f2与所述磷原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 22的取代基取代的3~12元脂杂环基;R d2选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或各自任选地被1、2、3、4或5个独立地选自R 22的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-12环烷基和3~12元脂杂环基;R 22选自:1)氧代基、卤族原子、氰基、-C(=O)R a4、-C(=O)OR a4、-C(=O)NR a4R b4、-C(=NR d4)NR a4R b4、-OR a4、-OC(=O)R a4、-OC(=O)OR c4、-OC(=O)NR a4R b4、-SR a4、-S(=O)R c4、-S(=O) 2R c4、磺酸基、-S(=O)NR a4R b4、-S(=O) 2NR a4R b4、-S(=O)(=NR d4)R c4、-NR a4R b4、-NR a4C(=O)R b4、-NR a4C(=O)OR c4、-NR e4C(=O)NR a4R b4、-NR e4C(=NR d4)NR a4R b4、-NR a4S(=O) 2R c4、-NR e4S(=O) 2NR a4R b4、硝基、-PR c4R f4、-P(=O)R c4R f4、膦酸基和=N-R d4;2)未被取代或任选地被1、2、3、4或5个独立地选自R 32的取代基取代的C 1-6烷基、C 1-6亚烷基、C 2-6烯基、C 2-6炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;R a4、R b4和R e4各自独立地选自:1)氢;2)未被取代或任选地被1、2、3、4或5个独立地选自R 32的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;或者,连接于同一氮原子的R a4和R b4与所述氮原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 32的取代基取代的3~10元脂杂环基;R c4和R f4各自独立地选自:未被取代或任选地被1、2、3、4或5个独立地选自R 32的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;或者,连接于同一磷原子的R c4和R f4与所述磷原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 32的取代基取代的3~10元脂杂环基;R d4选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2、3、4或5个独立地选自R 32的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;R 32选自:1)氧代基、卤族原子、氰基、-C(=O)R a6、-C(=O)OR a6、-C(=O)NR a6R b6、-C(=NR d6)NR a6R b6、-OR a6、-OC(=O)R a6、-OC(=O)OR c6、-OC(=O)NR a6R b6、-SR a6、-S(=O)R c6、-S(=O) 2R c6、磺酸基、-S(=O)NR a6R b6、-S(=O) 2NR a6R b6、-S(=O)(=NR d6)R c6、-NR a6R b6、-NR a6C(=O)R b6、-NR a6C(=O)OR c6、-NR e6C(=O)NR a6R b6、-NR e6C(=NR d6)NR a6R b6、-NR a6S(=O) 2R c6、-NR e6S(=O) 2NR a6R b6、硝基、-PR c6R f6、-P(=O)R c6R f6、膦酸基和=N-R d6;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 1-4亚烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;R a6、R b6和R e6各自独立地选自:1)氢;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;或者,连接于同一氮原子的R a6和R b6与所述氮原子一起形成未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的3~8元脂杂环基;R c6和R f6各自独立地选自:未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;或者,连接于同一磷原子的R c6和R f6与所述磷原子一起形成未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的3~8元脂杂环基;R d6选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基、3~8元脂杂环基;Cy B选自未被取代或任选地被1、2、3、4或5个独立地选自R 13的取代基取代的6~10元芳基或5~10元杂芳基;R 13选自:1)氧代基、卤族原子、氰基、-C(=O)R a3、-C(=O)OR a3、-C(=O)NR a3R b3、-C(=NR d3)NR a3R b3、-OR a3、-OC(=O)R a3、-OC(=O)OR c3、-OC(=O)NR a3R b3、-SR a3、-S(=O)R c3、-S(=O) 2R c3、磺酸基、-S(=O)NR a3R b3、-S(=O) 2NR a3R b3、-S(=O)(=NR d3)R c3、-NR a3R b3、-NR a3C(=O)R b3、-NR a3C(=O)OR c3、-NR e3C(=O)NR a3R b3、-NR e3C(=NR d3)NR a3R b3、-NR a3S(=O) 2R c3、-NR e3S(=O) 2NR a3R b3、硝基、-PR c3R f3、-P(=O)R c3R f3和膦酸基;2)未被取代或任选地被1、2、3、4、5或6个独立地选自R 23的取代基取代的C 1-6烷基、C 2-6烯基、C 2-6炔基、6~10元芳基、5~10元杂芳基、C 3-12环烷基和3~12元脂杂环基;3)分别与Cy B的芳基或杂芳基上相邻的两个成环原子相连的两个R 13取代基和与所述两个成环原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 23的取代基取代的C 5-12脂环烃基或5~12元脂杂环基;R a3、R b3和R e3各自独立地选自:1)氢;2)未被取代或任选地被1、2、3、4、5或6个独立地选自R 23的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-12环烷基和3~12元脂杂环基;或者,连接于同一氮原子的R a3和R b3与所述氮原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 23的取代基取代的3~12元脂杂环基;R c3和R f3各自独立地选自:未被取代或任选地被1、2、3、4或5个独立地选自R 23的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-12环烷基和3~12元脂杂环基;或者,连接于同一磷原子的R c3和R f3与所述磷原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 23的取代基取代的3~12元脂杂环基;R d3选自:1)氢、氰基、硝基和S(=O) 2R G;2)未被取代或各自任选地被1、2、3、4或5个独立地选自R 23的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-12环烷基和3~12元脂杂环基;R 23选自:1)氧代基、卤族原子、氰基、-C(=O)R a5、-C(=O)OR a5、-C(=O)NR a5R b5、-C(=NR d5)NR a5R b5、-OR a5、-OC(=O)R a5、-OC(=O)OR c5、-OC(=O)NR a5R b5、-SR a5、-S(=O)R c5、-S(=O) 2R c5、磺酸基、-S(=O)NR a5R b5、-S(=O) 2NR a5R b5、-S(=O)(=NR d5)R c5、-NR a5R b5、-NR a5C(=O)R b5、-NR a5C(=O)OR c5、-NR e5C(=O)NR a5R b5、-NR e5C(=NR d5)NR a5R b5、-NR a5S(=O) 2R c5、-NR e5S(=O) 2NR a5R b5、硝基、-PR c5R f5、-P(=O)R c5R f5、膦酸基和=N-R d5;2)未被取代或任选地被1、2、3、4或5个独立地选自R 33的取代基取代的C 1-6烷基、C 1-6亚烷基、C 2-6烯基、C 2-6炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;R a5、R b5和R e5各自独立地选自:1)氢;2)未被取代或任选地被1、2、3、4或5个独立地选自R 33的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;或者,连接于同一氮原子的R a5和R b5与所述氮原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 33的取代基取代的3~10元脂杂环基;R c5和R f5各自独立地选自:未被取代或任选地被1、2、3、4或5个独立地选自R 33的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;或者,连接于同一磷原子的R c5和R f5与所述磷原子一起形成未被取代或任选地被1、2、3、4或5个独立地选自R 33的取代基取代的3~10元脂杂环基;R d5选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2、3、4或5个独立地选自R 33的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;R 33选自:1)氧代基、卤族原子、氰基、-C(=O)R a7、-C(=O)OR a7、-C(=O)NR a7R b7、-C(=NR d7)NR a7R b7、-OR a7、-OC(=O)R a7、-OC(=O)OR c7、-OC(=O)NR a7R b7、-SR a7、-S(=O)R c7、-S(=O) 2R c7、磺酸基、-S(=O)NR a7R b7、-S(=O) 2NR a7R b7、-S(=O)(=NR d7)R c7、-NR a7R b7、-NR a7C(=O)R b7、-NR a7C(=O)OR c7、-NR e7C(=O)NR a7R b7、-NR e7C(=NR d7)NR a7R b7、-NR a7S(=O) 2R c7、-NR e7S(=O) 2NR a7R b7、硝基、-PR c7R f7、-P(=O)R c7R f7、膦酸基和=N-R d7;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 1-4亚烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;R a7、R b7和R e7各自独立地选自:1)氢;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;或者,连接于同一氮原子的R a7和R b7与所述氮原子一起形成未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的3~8元脂杂环基;R c7和R f7各自独立地选自:未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;或者,连接于同一磷原子的任一R c7和R f7与所述磷原子一起形成未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的3~8元脂杂环基;R d7选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-8环烷基和3~8元脂杂环基;R G选自:1)卤族原子、氧代基、氰基、羧基、羟基、C 1-4烷氧基、氨基、C 1-4烷基氨基、硝基、C 1-4烷硫基、磺酸基、C 1-4烷基亚砜基、C 1-4烷基砜基、C 1-4烷基氨基亚磺酰基和C 1-4烷基氨基磺酰基;2)未被取代或任选地被1、2、3或4个独立地选自氧代基、卤族原子、羟基、羟甲基、羧基、氰基、C 1-3烷氧基、氨基、C 1-3烷基氨基、硝基和磺酸基的基团取代的C 1-4烷基、C 1-4亚烷基、C 2-4烯基、C 2-4炔基、C 3-6环烷基和3~8元脂杂环基。
- 根据权利要求1所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1选自:氢、氟、氰基、甲基、乙基、1-丙基、异丙基、环丙基、甲氧基、乙氧基和环丙氧基;Cy A选自未被取代或任选地被1、2、3或4个独立地选自R 12的基团取代的苯基、萘基和5~10元杂芳基;所述5~10元杂芳基具有至少两个成环碳原子和1、2或3个独立地选自N、O和S的成环杂原子;R 12选自:1)氧代基、卤族原子、氰基、-C(=O)R a2、-C(=O)OR a2、-C(=O)NR a2R b2、-C(=NR d2)NR a2R b2、-OR a2、-NR a2R b2、-NR a2C(=O)R b2、-NR a2C(=O)OR c2、-NR e2C(=O)NR a2R b2、-NR e2C(=NR d2)NR a2R b2、-NR a2S(=O) 2R c2、-NR e2S(=O) 2NR a2R b2;2)未被取代或任选地被1、2、3或4个独立地选自R 22的取代基取代的C 1-6烷基、C 2-6烯基、C 2-6炔基、6~10元芳基、5~10元杂芳基、C 3-10环烷基和3~10元脂杂环基;3)分别与Cy A的芳基或杂芳基上相邻的两个成环原子相连的两个R 12取代基和与所述两个成环原子一起形成未被取代或任选地被1、2或3个独立地选自R 22的取代基取代的C 4-8脂环烃基或4~8元脂杂环基;R a2、R b2和R e2各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R 22的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;或者,连接于同一氮原子的R a2和R b2与所述氮原子一起形成未被取代或任选地被1、2或3个独立地选自R 22的取代基取代的3~8元脂杂环基;R c2独立地选自:未被取代或任选地被1、2或3个独立地选自R 22的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R d2选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或各自任选地被1、2或3个独立地选自R 22的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基、3~6元脂杂环基;R 22选自:1)氧代基、卤族原子、氰基、羧基、-C(=O)R a4、-C(=O)OR a4、-C(=O)NR a4R b4、-C(=NR d4)NR a4R b4、-OR a4、-S(=O) 2R c4、磺酸基、-S(=O) 2NR a4R b4、-S(=O)(=NR d4)R c4、-NR a4R b4、-NR a4C(=O)R b4、-NR e4C(=O)NR a4R b4、-NR e4C(=NR d4)NR a4R b4、-NR a4S(=O) 2R c4、-NR e4S(=O) 2NR a4R b4和=N-R d4;2)未被取代或任选地被1、2或3个独立地选自R 32的取代基取代的C 1-4烷基、C 1-4亚烷基、苯基、5~6元杂芳基、C 3-7环烷基和3~7元脂杂环基;R a4、R b4和R e4各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R 32的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;或者,连接于同一氮原子的R a4和R b4与所述氮原子一起形成未被取代或任选地被1、2或3个独立地选自R 32的取代基取代的3~6元脂杂环基;R c4独立地选自:未被取代或任选地被1、2或3个独立地选自R 32的取代基取代的C 1-4烷基苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R d4选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2或3个独立地选自R 32的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R 32选自:1)氧代基、卤族原子、氰基、-C(=O)R a6、-C(=O)OR a6、C(=O)NR a6R b6、-C(=NR d6)NR a6R b6、-OR a6、-S(=O) 2R c6、-S(=O) 2NR a6R b6、-S(=O)(=NR d6)R c6、-NR a6R b6、-NR a6C(=O)R b6、-NR e6C(=O)NR a6R b6、-NR e6C(=NR d6)NR a6R b6、-NR a6S(=O) 2R c6、-NR e6S(=O) 2NR a6R b6和=N-R d6;2)未被取代或任选地被1、2、3或4个独立地选自R G的取代基取代的C 1-4烷基、C 1-4亚烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R a6、R b6和R e6各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;或者,连接于同一氮原子的R a6和R b6与所述氮原子一起形成未被取代或任选地被1、2或3个独立地选自R G的取代基取代的3~6元脂杂环基;R c6独立地选自:未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R d6选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基、3~6元脂杂环基;Cy B选自未被取代或任选地被1、2、3或4个独立地选自R 12的基团取代的苯基、萘基和5~10元杂芳基;所述5~10元杂芳基具有至少一个成环碳原子和1、2或3个独立地选自N、O和S的成环杂原子;R 13选自:1)氧代基、卤族原子、氰基、-C(=O)R a3、-C(=O)OR a3、-C(=O)NR a3R b3、-C(=NR d3)NR a3R b3、-OR a3、-NR a3R b3、-NR a3C(=O)R b3、-NR e3C(=O)NR a3R b3、-NR e3C(=NR d3)NR a3R b3、-NR a3S(=O) 2R c3、-NR e3S(=O) 2NR a3R b3;2)未被取代或任选地被1、2、3或4个独立地选自R 23的取代基取代的C 1-6烷基、C 2-6烯基、C 2-6炔基、6~10元芳基、5~10元杂芳基、C 3-10环烷基和3~10元脂杂环基;3)分别与Cy B的芳基或杂芳基上相邻的两个成环原子相连的两个R 13取代基和与所述两个成环原子一起形成未被取代或任选地被1、2或3个独立地选自R 23的取代基取代的C 4-8脂环烃基或4~8元脂杂环基;R a3、R b3和R e3各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R 23的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;或者,连接于同一氮原子的R a3和R b3与所述氮原子一起形成未被取代或任选地被1、2或3个独立地选自R 23的取代基取代的3~8元脂杂环基;R c3独立地选自:未被取代或任选地被1、2或3个独立地选自R 23的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R d3选自:1)氢、氰基、硝基和S(=O) 2R G;2)未被取代或各自任选地被1、2或3个独立地选自R 23的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基、3~6元脂杂环基;R 23选自:1)氧代基、卤族原子、氰基、羧基、-C(=O)R a5、-C(=O)OR a5、-C(=O)NR a5R b5、-C(=NR d5)NR a5R b5、-OR a5、-S(=O) 2R c5、磺酸基、-S(=O) 2NR a5R b5、-S(=O)(=NR d5)R c5、-NR a5R b5、-NR a5C(=O)R b5、-NR e5C(=O)NR a5R b5、-NR e5C(=NR d5)NR a5R b5、-NR a5S(=O) 2R c5、-NR e5S(=O) 2NR a5R b5和=N-R d5;2)未被取代或任选地被1、2或3个独立地选自R 33的取代基取代的C 1-6烷基、C 1-6亚烷基、苯基、5~6元杂芳基、C 3-7环烷基和3~7元脂杂环基;R a5、R b5和R e5各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R 33的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;或者,连接于同一氮原子的R a5和R b5与所述氮原子一起形成未被取代或任选地被1、2或3个独立地选自R 33的取代基取代的3~6元脂杂环基;R c5独立地选自:未被取代或任选地被1、2或3个独立地选自R 33的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R d5选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2或3个独立地选自R 33的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R 33选自:1)氧代基、卤族原子、氰基、-C(=O)R a7、-C(=O)OR a7、-C(=O)NR a7R b7、-C(=NR d7)NR a7R b7、-OR a7、-S(=O) 2R c7、-S(=O) 2NR a7R b7、-S(=O)(=NR d7)R c7、-NR a7R b7、-NR a7C(=O)R b7、-NR e7C(=O)NR a7R b7、-NR e7C(=NR d7)NR a7R b7、-NR a7S(=O) 2R c7、-NR e7S(=O) 2NR a7R b7和=N-R d7;2)未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、C 1-4亚烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R a7、R b7和R e7各自独立地选自:1)氢;2)未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;或者,连接于同一氮原子的R a7和R b7与所述氮原子一起形成未被取代或任选地被1、2或3个独立地选自R G的取代基取代的3~6元脂杂环基;R c7独立地选自:未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、C 2-4烯基、C 2-4炔基、苯基、5~6元杂芳基、C 3-6环烷基和3~6元脂杂环基;R d7选自:1)氢、氰基、硝基和-S(=O) 2R G;2)未被取代或任选地被1、2或3个独立地选自R G的取代基取代的C 1-4烷基、苯基、5-6元杂芳基、C 3-6环烷基和3-6元脂杂环基;R G选自:1)卤族原子、氧代基、氰基、羧基、羟基、C 1-4烷氧基、氨基、C 1-4烷基氨基、磺酸基、C 1-4烷基砜基和C 1-4烷基氨基磺酰基;2)未被取代或任选地被1、2或3个独立地选自氧代基、卤族原子、羟基、羟甲基、羧基、氰基、C 1-3烷氧基、氨基、C 1-3烷基氨基取代的C 1-4烷基、C 1-4亚烷基、C 2-4烯基、C 2-4炔基、C 3-6环烷基和3~8元脂杂环基。
- 根据权利要求2所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1选自氢、氟、氰基、甲基和甲氧基;Cy A为未被取代的或任选地被1、2或3个R 12取代的苯基、5元或6元杂芳基,所述5元或6元杂芳基包含1个或2个选自N、S的杂原子;Cy B为未被取代的或任选地被1、2、3或4个独立地选自R 13的取代基取代的苯基或5~6元杂芳基,所述5~6元杂芳基包含1、2或3个选自N、S的成环杂原子。R 12选自:1)氧代基、卤族原子、氰基、-C(=O)R a2、-C(=O)NR a2R b2、-C(=NR d2)NR a2R b2、-OR a2、-NR a2R b2、-NR a2C(=O)R b2、-NR a2C(=O)OR c2、-NR e2C(=O)NR a2R b2、-NR e2C(=NR d2)NR a2R b2、-NR a2S(=O) 2R c2、-NR e2S(=O) 2NR a2R b2;2)未被取代或任选地被1、2、3或4个独立地选自R 22的取代基取代的C 1-6烷基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;3)分别与Cy A的芳基或杂芳基上相邻的两个成环原子相连的两个R 12取代基和与所 述两个成环原子一起形成未被取代或任选地被1、2或3个独立地选自R 22的取代基取代的C 5、C 6、C 7单环脂环烃基或5元、6元、7元单环脂杂环基;R 13选自:1)氧代基、卤族原子、氰基、-C(=O)R a3、-C(=O)NR a3R b3、-C(=NR d3)NR a3R b3、-OR a3、-NR a3R b3、-NR a3C(=O)R b3、-NR e3C(=O)NR a3R b3、-NR e3C(=NR d3)NR a3R b3、-NR a3S(=O) 2R c3、-NR e3S(=O) 2NR a3R b3;2)未被取代或任选地被1、2、3或4个独立地选自R 23的取代基取代的C 1-6烷基、苯基、5~6元杂芳基、C 3-10环烷基和3~10元脂杂环基;3)分别与Cy B的芳基或杂芳基上相邻的两个成环原子相连的两个R 13取代基和与所述两个成环原子一起形成未被取代或任选地被1、2或3个独立地选自R 23的取代基取代的C 5、C 6、C 7单环脂环烃基或5元、6元、7元单环脂杂环基。
- 根据权利要求2所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1选自氢、氟、氰基、甲基和甲氧基;Cy A选自,2)未被取代的或任选地被1、2或3个独立地选自R 12的取代基取代的苯基、吡啶基、嘧啶基、吡唑基、咪唑基、噻唑基、异噻唑基、噁唑基或异噁唑基,其中:(a)各R 12分别独立地选自氟、氯、不为氢的R G1、OR G1;或者,或者,Cy A包含2或3个R 12,其中1个R 12选自上述结构中的一种,其余R 12独立地选自:氟、氯、不为氢的R G1、-OR G1;其中,X选自CH和N;Y选自-CH 2-、NH和O;E 1和E 2分别独立地选自-CH 2-和羰基,E 1和E 2不同时为羰基;R G2选自氢、-OR G1和-N(R G1) 2;各R G1独立地选自:1)氢、甲基、乙基、异丙基、环丙基、3-氧杂环丁基、和3-甲基-3-氮杂环丁基;2)连接于同一个原子的两个R G1基团与它们共同连接的原子一起形成一个C 3-6单环烃环或3~6元单环脂杂环;3)分别连接于同一单环上的两个不同成环原子的两个R G1基团相连接,并与所述单环的部分成环原子一起形成环状结构,相连的两个R G1基团共同形成C 2、C 3或C 4的亚烷基;Cy B为任选地被1、2或3个独立地选自R 13的取代基取代的苯基、吡啶基、嘧啶基、哒嗪基、吡唑基、咪唑基、噻唑基、异噻唑基、噻吩基;R 13选自:1)氧代基、卤族原子、氰基、-C(=O)R a3、-C(=O)NR a3R b3、-C(=NR d3)NR a3R b3、-OR a3、-NR a3R b3、-NR a3C(=O)R b3、-NR e3C(=O)NR a3R b3、-NR e3C(=NR d3)NR a3R b3、-NR a3S(=O) 2R c3、-NR e3S(=O) 2NR a3R b3;2)未被取代或任选地被1、2、3或4个独立地选自R 23的取代基取代的C 1-6烷基、苯基、5~6元杂芳基、C 3-6单环环烷基和3-6元单环脂杂环基;3)分别与Cy B的芳基或杂芳基上相邻的两个成环原子相连的两个R 13取代基和与所述两个成环原子一起形成未被取代或任选地被1、2或3个独立地选自R 23的取代基取代的C 5、C 6、C 7单环脂环烃基或5元、6元、7元单环脂杂环基。
- 根据权利要求1所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1选自氢、氟、氰基、甲基和甲氧基;Cy A为未被取代的或任选地被1、2或3个独立地选自R 12的取代基取代的苯基、吡啶基、嘧啶基、吡唑基、咪唑基、噻唑基或异噻唑基,其中,1)各R 12独立地选自:氟、氯、不为氢的R G1、OR G1,或者,2)Cy A包含1个R 12,所述R 12选自下列结构中的一种:或者,Cy A包含2或3个R 12,其中1个R 12选自上述结构中的一种,其余R 12独立地选自:氟、氯、不为氢的R G1、OR G1;各R G1独立地选自:1)氢,2)甲基、乙基、异丙基、环丙基、3-氧杂环丁基和3-甲基-3-氮杂环丁基,其任选被羟基、C 1-6烷氧基或氨基取代;Cy B选自下列结构中的一种:R a3和R b3独立地选自氢、C 1-6烷基和C 1-6环烷基,或者,与相邻的两个成环原子相连的R a3和R b3和所述两个成环原子一起形成未取代的5~6元脂环烃基或未取代的5~6元脂杂环基。
- 根据权利要求1所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1选自氢、氟、氰基、甲基和甲氧基;Cy A为未被取代的或任选地被1、2或3个独立地选自R 12的取代基取代的苯基、吡啶基、嘧啶基、吡唑基、咪唑基、噻唑基、异噻唑基或由 表示的苯环与5-7元饱和脂杂环稠合的双环,或由 表示的吡啶环与5-7元饱和脂杂环稠合的双环,其中Z为1-3个选自氮和氧的杂原子;当Z=N时,N任选连接Ry基团,Ro选自氧代、F、氨基、任选被取代的C 1-3烷基,所述脂杂环可再与另一个含N杂原子的5-6元饱和脂杂环形成并环,其中,1)当Cy A包含1个R 12,所述R 12选自下列结构中的一种:2)当Cy A包含一个以上的R 12时,其余R 12独立地选自:氟、C 1-6烷基、C 1-6烷氧基、C 1-6烷基氨基甲基;Cy B选自下列结构中的一种:R a3和R b3独立地选自氢、任选被取代的C 1-6烷基和C 3-6环烷基,或者R a3和R b3与相连的N原子共同形成任选被取代的4-6元饱和脂杂环基;上述任选被取代的情形中的取代基选自氟、羟基、C 1-6烷基、被F取代的C 1-6烷基;R y选自H、C 1-6烷基、被羟基、卤素取代的C 1-6烷基、C 3-6环烷基、含氮的4-6元饱和脂杂环基、含氧的5-6元饱和脂杂环基、-C(=O)Rs,Rs选自任选被羟基、氨基、含氮脂杂环基取代的C 1-6烷基。
- 根据权利要求1-6任一项所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,Cy A选自苯基、吡啶基、嘧啶基、噻唑基或由 表示的苯环与5-7元饱和脂杂环稠合的双环,或由 表示的吡啶环与5-7元饱和脂杂环稠合的双环,其中Z为1-3个,选自氮和氧;当Z=N时,其任选连接Ry基团,Ro选自氧代、F、氨基、任选被取代的C 1-3烷基,所述饱和脂杂环可再与另一个含N杂原子的5-6元饱和脂杂环形成并环;R y选自H、C 1-6烷基、被羟基、卤素取代的C 1-6烷基、C 3-6环烷基、含氮的4-6元饱和脂杂环基、含氧的5-6元饱和脂杂环基、-C(=O)Rs,Rs选自任选被羟基、氨基、含氮脂杂环基取代的C 1-6烷基;当Cy A选自苯基、吡啶基、嘧啶基或噻唑基时,R 12选自
- 根据权利要求1-9任一项所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,Cy B选自苯基,所述苯基任选地被选自以下的基团所取代:H、F、-CN或任选被取代的C 1-3烷基、任选被取代的C 1-3烷氧基取代、任选被取代的C 3-6环烷基氧基和-C(=O)NR a3R b3,R a3和R b3独立地选自氢、C 1-6烷基和任选被取代的C 3-6环烷基,或者R a3和R b3与N原子共同形成任选被取代的4~5元脂杂环基。
- 根据权利要求1所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,R 1为H;Cy A选自:1)未被取代的或任选地被1、2或3个独立地选自R 12的取代基取代的苯基、吡啶基、嘧啶基,各R 12独立地选自:氟、氯、不为氢的R G1、OR G1;2)任选地被1、2或3个独立地选自R 12的取代基取代的苯基、吡啶基、嘧啶基,其中一个选自下列基团,其他R 12独立地选自:氟、氯、不为氢的R G1、OR G1;3)下列结构,且其中的苯基、吡啶基未被取代的或任选地被1或2个独立地选自R 12的取代基取代。Cy B选自其中,R a3选自甲基、乙基、二氟甲基、三氟甲基、异丙基和环丙基;优选自甲基、乙基。E 1独立地选自:-CH 2-和氧;R G3独立地选自:氢、氧代基、甲基、乙基、异丙基、环丙基、3-氧杂环丁基和3-甲基-3-氮杂环丁基;R 13选自氢、氟、氰基和-C(=O)-N(R G3) 2;优选自氢和氰基;各R G3独立地选自:1)氢、甲基、乙基、异丙基、环丙基、氧杂环丁基、氧杂环戊基、氮杂环丁基或氮杂环戊基;2)连接于同一个原子的两个R G3基团与它们共同连接的原子一起形成一个C 3-6单环烃环或3~6元单环脂杂环;3)分别连接于同一单环上的两个不同成环原子的两个R G3基团相连接,并与所述单环的部分成环原子一起形成环状结构,相连的两个R G3基团共同形成C 2、C 3或C 4的亚烷基,2、3或4元氧杂亚烷基,或2、3或4元氮杂亚烷基;并且,当R G3不为氢时,R G3未被取代或者独立地被1、2或3个任选自氧代基、氟、羟基、甲氧基、氨基、甲基氨基、二甲基氨基、甲基、乙基或氰基的取代基取代。
- 根据权利要求1-12任一项所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,其中,当Cy A为苯基,且R 12为杂环基时,R 12连接在苯基的对位或间位。
- 一种药物组合物,包含权利要求1至14中任一项所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,以及药学上可接受的载体。
- 权利要求1至14中任一项所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,或权利要求15所述的药物组合物在制备预防或治疗由HPK1介导的疾病的药物中的用途。
- 权利要求1至14中任一项所述的化合物或其药学上可接受的盐、水合物、溶剂化物、活性代谢物、多晶型物、同位素标记物、异构体或前药,或权利要求15所述的药物组合物在制备预防或治疗以下疾病的药物中的用途,所述疾病选自良性或恶性肿瘤、骨髓增生异常综合征以及病毒引发的疾病。
- 根据权利要求17所述的用途,其中,所述良性或恶性肿瘤选自白血病、淋巴瘤、多发性骨髓瘤、肺癌、肝细胞癌、胆管癌、胆囊癌、胃癌、结直肠癌、小肠平滑肌肉瘤、乳腺癌、卵巢癌、宫颈癌、子宫内膜癌、阴道癌、恶性畸胎瘤、胰腺癌、胰腺导管腺癌、鼻咽癌、口腔癌、喉癌、食管鳞状细胞癌、甲状腺癌、肾癌、膀胱癌、恶性脑瘤、横纹肌肉瘤、骨肉瘤、软骨肉瘤、骨纤维肉瘤、恶性胸腺瘤、恶性外周神经鞘膜瘤、前列腺癌、睾丸癌、阴茎癌,以及皮肤良性与恶性肿瘤。
- 根据权利要求17所述的用途,其中,所述病毒选自肝炎病毒、人类免疫缺陷病毒、人乳头瘤病毒、单纯疱疹病毒、麻疹病毒、诺如病毒、博卡病毒、柯萨奇病毒、埃博拉病毒、肠道病毒、淋巴细胞性脑膜炎病毒、流行性感冒病毒、SARS病毒和新型冠状病毒。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020227034765A KR20220151663A (ko) | 2020-11-03 | 2021-11-03 | 피라졸로피리다지논 화합물, 그의 약학적 조성물 및 그의 용도 |
CA3191362A CA3191362A1 (en) | 2020-11-03 | 2021-11-03 | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof |
US18/044,501 US20230322789A1 (en) | 2020-11-03 | 2021-11-03 | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof |
AU2021373162A AU2021373162B2 (en) | 2020-11-03 | 2021-11-03 | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof |
EP21888601.8A EP4223759A4 (en) | 2020-11-03 | 2021-11-03 | PYRAZOLOPYRIDAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE |
JP2022560929A JP2023520595A (ja) | 2020-11-03 | 2021-11-03 | ピラゾロピリダジノン化合物、その医薬組成物及びその用途 |
CN202180055097.4A CN116157128A (zh) | 2020-11-03 | 2021-11-03 | 吡唑并哒嗪酮化合物、其药物组合物及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011209391.XA CN114437074A (zh) | 2020-11-03 | 2020-11-03 | 一种化合物、含该化合物的药物组合物及其用途 |
CN202011209391.X | 2020-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022095904A1 true WO2022095904A1 (zh) | 2022-05-12 |
Family
ID=81361363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/128460 WO2022095904A1 (zh) | 2020-11-03 | 2021-11-03 | 吡唑并哒嗪酮化合物、其药物组合物及其用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230322789A1 (zh) |
EP (1) | EP4223759A4 (zh) |
JP (1) | JP2023520595A (zh) |
KR (1) | KR20220151663A (zh) |
CN (2) | CN114437074A (zh) |
AU (1) | AU2021373162B2 (zh) |
CA (1) | CA3191362A1 (zh) |
WO (1) | WO2022095904A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11897878B2 (en) | 2018-10-31 | 2024-02-13 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11925631B2 (en) | 2018-10-31 | 2024-03-12 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018049200A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018102366A1 (en) | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
WO2018183964A1 (en) | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
WO2019206049A1 (en) | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Hpk1 inhibitors, preparation method and application thereof |
WO2019238067A1 (en) | 2018-06-13 | 2019-12-19 | Beigene, Ltd. | Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04307542A (ja) * | 1991-04-04 | 1992-10-29 | Konica Corp | 新規な写真用カプラー |
US7601718B2 (en) * | 2003-02-06 | 2009-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US20180072741A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
-
2020
- 2020-11-03 CN CN202011209391.XA patent/CN114437074A/zh active Pending
-
2021
- 2021-11-03 JP JP2022560929A patent/JP2023520595A/ja active Pending
- 2021-11-03 EP EP21888601.8A patent/EP4223759A4/en active Pending
- 2021-11-03 CA CA3191362A patent/CA3191362A1/en active Pending
- 2021-11-03 US US18/044,501 patent/US20230322789A1/en active Pending
- 2021-11-03 WO PCT/CN2021/128460 patent/WO2022095904A1/zh unknown
- 2021-11-03 AU AU2021373162A patent/AU2021373162B2/en active Active
- 2021-11-03 CN CN202180055097.4A patent/CN116157128A/zh active Pending
- 2021-11-03 KR KR1020227034765A patent/KR20220151663A/ko unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018049200A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
WO2018102366A1 (en) | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
WO2018183964A1 (en) | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
WO2019206049A1 (en) | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Hpk1 inhibitors, preparation method and application thereof |
WO2019238067A1 (en) | 2018-06-13 | 2019-12-19 | Beigene, Ltd. | Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
Non-Patent Citations (24)
Title |
---|
ALZABIN, S ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 59, 2010, pages 419 - 429 |
ALZABIN, S ET AL., J. IMMUNOL., vol. 182, 2009, pages 6187 - 6194 |
BALTIWALLA, F. M. ET AL., MOL. MED., vol. 11, 2005, pages 21 - 29 |
CHEN-DEUTSCH, X ET AL., CELL CYCLE, vol. 11, 2012, pages 1364 - 1373 |
CHEN-DEUTSCH, X ET AL., LEUK. RES., vol. 36, 2012, pages 884 - 888 |
DI BARTOLO, V ET AL., J. EXP. MED., vol. 204, 2007, pages 681 - 691 |
HERNANDEZ, S ET AL., CELL REPORTS, vol. 25, 2018, pages 80 - 94 |
HU, M. C. ET AL., GENES DEV, vol. 10, 1996, pages 2251 - 2264 |
KEIFER, F ET AL., THE EMBO JOURNAL, vol. 15, 1996, pages 7013 - 7025 |
KONIGSBERGER, S ET AL., PLOS ONE, vol. 5, 2010, pages 12468 |
LASSERRE, R ET AL., J CELL BIOL., vol. 195, 2011, pages 839 - 853 |
LASSERRE, R ET AL., J. CELL BIOL., vol. 195, 2011, pages 839 - 853 |
LIU, J ET AL., PLOS ONE, vol. 14, 2019, pages 0212670 |
QIAN, Y ET AL., AM J. DERMATOPATHOL., vol. 33, 2011, pages 681 - 686 |
SAUER, K ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 45207 - 45216 |
SAWASDIKOSOL, S ET AL., IMMUNOL. RES., vol. 54, 2012, pages 262 - 265 |
See also references of EP4223759A4 |
SHUI, J. ET AL., NATURE IMMUNO, vol. 8, 2007, pages 84 - 91 |
STOECKMAN, A. K. ET AL., GENES IMMUN, vol. 7, 2006, pages 583 - 591 |
TSUJI, S ET AL., J. EXP. MED., vol. 194, 2001, pages 529 - 539 |
WANG, X ET AL., J. BIOL. CHEM., vol. 287, 2012, pages 34091 - 34100 |
WANG. Y ET AL., MOL. MED. REP., vol. 5, 2012, pages 260 - 265 |
YANG, H.S. ET AL., MOL. CELL BIOL., vol. 26, 2006, pages 1297 - 1306 |
ZHANG, Q ET AL., J. AUTOIMMUN., vol. 37, 2011, pages 180 - 189 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11897878B2 (en) | 2018-10-31 | 2024-02-13 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11925631B2 (en) | 2018-10-31 | 2024-03-12 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
Also Published As
Publication number | Publication date |
---|---|
CN114437074A (zh) | 2022-05-06 |
KR20220151663A (ko) | 2022-11-15 |
EP4223759A1 (en) | 2023-08-09 |
CN116157128A (zh) | 2023-05-23 |
JP2023520595A (ja) | 2023-05-17 |
AU2021373162A1 (en) | 2023-04-13 |
CA3191362A1 (en) | 2022-05-12 |
US20230322789A1 (en) | 2023-10-12 |
AU2021373162B2 (en) | 2024-02-22 |
EP4223759A4 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6478991B2 (ja) | Ido阻害剤 | |
TWI659021B (zh) | Kras g12c之抑制劑 | |
CN104910161B (zh) | 作为jak抑制剂的吡唑并嘧啶化合物和方法 | |
TWI458723B (zh) | 1,2-雙取代雜環化合物 | |
TWI662026B (zh) | 吡啶酮類衍生物、其製備方法及其在醫藥上的應用 | |
TWI648272B (zh) | 經取代之四氫咔唑及咔唑甲醯胺化合物 | |
US11267815B2 (en) | Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof | |
WO2022095904A1 (zh) | 吡唑并哒嗪酮化合物、其药物组合物及其用途 | |
CN107312009B (zh) | 喹啉类化合物、其制备方法、中间体、药物组合物和应用 | |
WO2021249519A1 (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
WO2018214866A1 (zh) | 一种氮杂芳基衍生物、其制备方法和在药学上的应用 | |
WO2022127199A1 (zh) | 一类抑制rna解旋酶dhx33的多环化合物及其应用 | |
WO2022105921A1 (zh) | 一类嘧啶并杂环类化合物、制备方法和用途 | |
WO2019024876A1 (zh) | 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用 | |
WO2020221209A1 (zh) | 一种cd73抑制剂,其制备方法和应用 | |
CN111247137A (zh) | 一种嘧啶类化合物、其制备方法及其医药用途 | |
WO2022222911A1 (zh) | 嘧啶酮化合物及其用途 | |
WO2021017880A1 (zh) | 一类靶向stat3双功能磷酸化位点的三芳香环类化合物及其应用 | |
WO2013189241A1 (zh) | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 | |
WO2023083362A1 (zh) | 一种治疗肿瘤的药物 | |
TWI707853B (zh) | 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途 | |
WO2022206730A1 (zh) | 嘧啶并吡嗪酮化合物及其用途 | |
CN115838373A (zh) | 氮杂吲唑大环化合物及其用途 | |
WO2022253311A1 (zh) | Hpk1抑制剂及其应用 | |
WO2024041634A1 (zh) | 三环类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21888601 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022560929 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227034765 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3191362 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021373162 Country of ref document: AU Date of ref document: 20211103 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021888601 Country of ref document: EP Effective date: 20230501 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |